Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44725 | 0.88 | ALDH1A1 (0.50) | ALDH1A1PKMKMT2AMAPTHSD17B10 | |
| SCHEMBL21768790 | 0.88 | ALDH1A1 (0.51) | ALDH1A1PKMKMT2AMAPTHSD17B10 | |
| SCHEMBL2002797 | 0.86 | ALDH1A1 (0.49) | ALDH1A1PKMKMT2AMAPTHSD17B10 | |
| SCHEMBL4551765 | 0.82 | LMNA (0.41) | ALDH1A1PKMKMT2AMAPTHSD17B10 | |
| SCHEMBL177980 | 0.81 | ALDH1A1 (0.48) | ALDH1A1PKMKMT2AMAPTHSD17B10 | |
| SCHEMBL1752117 | 0.81 | ALDH1A1 (0.48) | ALDH1A1PKMKMT2AMAPTHSD17B10 | |
| SCHEMBL27170468 | 0.81 | ALDH1A1 (0.48) | ALDH1A1PKMKMT2AMAPTHSD17B10 | |
| Hydrogen Sulfide SCHEMBL20305480 | 0.80 | ALDH1A1 (0.47) | ALDH1A1PKMKMT2AMAPTHSD17B10 | |
| SCHEMBL3490799 | 0.79 | ALDH1A1 (0.46) | ALDH1A1PKMKMT2AMAPT | |
| SCHEMBL745826 | 0.79 | ALDH1A1 (0.46) | ALDH1A1PKMKMT2AMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 578 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281628-A1 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-11 | — | — | US | claimed |
| EP-4392087-A2 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-03 | — | — | EP | claimed |
| WO-2023028082-A2 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2009077438-A1 | METHOD FOR PREPARING PROTEIN CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2009-06-25 | — | — | WO | claimed |
| EP-1578450-A4 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2009-06-17 | — | — | EP | claimed |
| US-20060127310-A1 | Amplification of biotin-mediated targeting | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD. | 2006-06-15 | — | — | US | claimed |
| EP-1578450-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | Access Pharmaceuticals Australia Pty Ltd (AU) | 2005-09-28 | — | — | EP | claimed |
| WO-2005086775-A2 | LUMEN-EXPOSED MOLECULES AND METHODS FOR TARGETED DELIVERY | UTAH VENTURES II, L.P. (US) | 2005-09-22 | — | — | WO | claimed |
| US-20040146516-A1 | Lumen-exposed molecules and methods for targeted delivery | UTAH VENTURES II L.P. | 2004-07-29 | — | — | US | claimed |
| EP-1206251-A4 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2004-06-30 | — | — | EP | claimed |
| WO-2004045647-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2004-06-03 | — | — | WO | claimed |
| EP-1206251-A1 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 2002-05-22 | — | — | EP | claimed |
| WO-2000066090-A1 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES | BIOTECH AUSTRALIA PTY LIMITED (AU) | 2000-11-09 | — | — | WO | claimed |
| EP-0929316-A4 | NOVEL PRODUCT AND PROCESS FOR T LYMPHOCYTE VETO | NAT JEWISH CT IMMUN & RESPIRAT (US) | 2000-10-11 | — | — | EP | claimed |
| EP-0929316-A1 | NOVEL PRODUCT AND PROCESS FOR T LYMPHOCYTE VETO | NATIONAL JEWISH CENTER FOR IMMUNOLOGY AND RESPIRATORY MEDICINE (US) | 1999-07-21 | — | — | EP | claimed |
| WO-1997037687-A1 | NOVEL PRODUCT AND PROCESS FOR T LYMPHOCYTE VETO | NATIONAL JEWISH CENTER FOR IMMUNOLOGY AND RESPIRATORY MEDICINE (US) | 1997-10-16 | — | — | WO | claimed |
| EP-0473689-B1 | THROMBUS-TARGETED COMPLEXES OF PLASMINOGEN ACTIVATOR AND FIBRIN FRAGMENTS | UNIV TEMPLE (US) | 1994-12-14 | — | — | EP | claimed |
| EP-0308936-B1 | Antibody heteroconjugates for the killing of HIV-infected cells | BRISTOL MYERS SQUIBB CO (US) | 1994-07-06 | — | — | EP | claimed |
| EP-0184701-B1 | A method for determining a ligand | HOECHST CELANESE CORP (US) | 1994-06-08 | — | — | EP | claimed |
| JP-8126489-A | — | — | None | — | — | JP | disclosed |
| JP-2145199-A | — | — | None | — | — | JP | disclosed |
| JP-2173000-A | — | — | None | — | — | JP | disclosed |
| JP-8053499-A | — | — | None | — | — | JP | disclosed |
| US-20250281628-A1 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4392087-A2 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20230302127-A1 | TAU VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | OTHAIR PROTHENA LTD (IE) | 2023-09-28 | — | — | US | disclosed |
| US-20230248852-A1 | Nanoparticle Photoacoustic Imaging Agents | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-08-10 | — | — | US | disclosed |
| US-11598774-B2 | Methods of diagnosis and treatment of Alzheimer's Disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| WO-2023028082-A2 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-02 | — | — | WO | disclosed |
| US-11555051-B2 | Dithioamine reducing agents | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-01-17 | — | — | US | disclosed |
| US-11041013-B2 | Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis | CEL-SCI CORPORATION (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210054446-A1 | Promer for Real-Time Detection of Nucleic Acid or Protein and Method of detecting Nucleic Acid or Protein Using the Same | NURIBIO CO., LTD. (KR) | 2021-02-25 | — | — | US | disclosed |
| US-20200088724-A1 | METHODS OF DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3521450-A1 | METHOD FOR DETECTING SMALL RNAS OR PROTEINS ASSOCIATED WITH SMALL RNAS | Nuribio Co., Ltd. (KR) | 2019-08-07 | — | — | EP | disclosed |
| US-20190226033-A1 | Promer for Real-Time Detection of Nucleic Acid or Protein and Method of detecting Nucleic Acid or Protein Using the Same | NURIBIO CO., LTD. (KR) | 2019-07-25 | — | — | US | disclosed |
| US-20190153025-A1 | Dithioamine Reducing Agents | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2019-05-23 | — | — | US | disclosed |
| EP-3418393-A1 | SINGLE-STRANDED NUCLEIC ACID FOR DETECTING NUCLEIC ACID OR PROTEIN IN REAL TIME AND DETECTION METHOD USING SAME | Nuribio Co., Ltd. (KR) | 2018-12-26 | — | — | EP | disclosed |
| WO-2018081085-A1 | METHODS OF DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-03 | — | — | WO | disclosed |
| EP-2874663-B1 | NANOCONSTRUCTS WITH PHARMACOLOGICAL ACTIVITY | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2018-01-10 | — | — | EP | disclosed |
| EP-2254588-B1 | METHODS OF PREPARATION AND COMPOSITION OF PEPTIDE CONSTRUCTS USEFUL FOR TREATMENT OF RHEUMATOID ARTHRITIS | CEL-SCI CORP (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9757398-B2 | Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphin-gosine-1-phosphate | EUROESPES BIOTECNNOLOGIA, S.L. (ES) | 2017-09-12 | — | — | US | disclosed |
| US-20170252365-A1 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF | WHITEHEAD BIOMEDICAL INST (US) | 2017-09-07 | — | — | US | disclosed |
| US-9732101-B2 | Bioreversible boronates for delivery of molecules into cells | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-2551263-B1 | THIOSULFONATE COMPOUND, REVERSIBLY CATIONIZING AGENT FOR PROTEINS AND/OR PEPTIDES, AND METHOD FOR SOLUBILIZATION | NAT UNIV CORP OKAYAMA UNIV (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-20160331774-A1 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF | WHITEHEAD BIOMEDICAL INST (US) | 2016-11-17 | — | — | US | disclosed |
| US-9457047-B2 | Immunomodulating compositions and methods of use thereof | WHITEHEAD INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| US-9371521-B2 | Substituted pyrazinedithiol reducing agents | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160158330-A1 | METHODS OF PREPARATION AND COMPOSITION OF PEPTIDE CONSTRUCTS USEFUL FOR TREATMENT OF RHEUMATOID ARTHRITIS | CEL-SCI CORPORATION (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160083706-A1 | BORONATE-MEDIATED DELIVERY OF MOLECULES INTO CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| EP-2018398-B1 | ANTI-ACHARAN SULFATE ANTIBODY AND ITS APPLICATION | SEIKAGAKU KOGYO CO LTD (JP) | 2016-03-23 | — | — | EP | disclosed |
| EP-2190478-B1 | DKK1 ONCOGENE AS THERAPEUTIC TARGET FOR CANCER AND A DIAGNOSING MARKER | ONCOTHERAPY SCIENCE INC (JP) | 2016-03-23 | — | — | EP | disclosed |
| EP-1816200-B1 | Postweaning multisystemic wasting syndrome virus for pigs | MERIAL SAS (FR) | 2016-03-09 | — | — | EP | disclosed |
| US-9279020-B2 | Inotropic antibodies and therapeutic uses thereof | XU KAI YUAN (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2018399-B1 | ANTI-2-O-DESULFATED ACHARAN SULFATE ANTIBODY AND ITS APPLICATION | SEIKAGAKU KOGYO CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-20160024122-A1 | BIOREVERSIBLE BORONATES FOR DELIVERY OF MOLECULES INTO CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-9234048-B2 | Boronate-mediated delivery of molecules into cells | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150376591-A1 | SUBSTITUTED PYRAZINE DITHIOL REDUCING AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2015-12-31 | — | — | US | disclosed |
| US-20150307544-A1 | DITHIOAMINE REDUCING AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-29 | — | — | US | disclosed |
| US-9150902-B2 | Method for determination of N-deacetylase/N-sulfotransferase activity | SEIKAGAKU CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150267196-A1 | BIODEGRADABLE HYDROGEL FOR POLYNUCLEOTIDE DELIVERY | UNIV CASE WESTERN RESERVE (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150224061-A1 | NANOCONSTRUCTS WITH PHARMACOLOGICAL ACTIVITY | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2015-08-13 | — | — | US | disclosed |
| US-9090662-B2 | Dithioamine reducing agents | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150175709-A1 | Inotropic Antibodies And Therapeutic Uses Thereof | XU KAI YUAN (US) | 2015-06-25 | — | — | US | disclosed |
| EP-2874663-A1 | NANOCONSTRUCTS WITH PHARMACOLOGICAL ACTIVITY | Università Degli Studi Di Milano - Bicocca (IT) | 2015-05-27 | — | — | EP | disclosed |
| US-9034337-B2 | Treatment and delay of outset of synucleinopathic and amyloidogenic disease | PROTHENA BIOSCIENCES LIMITED (IE) | 2015-05-19 | — | — | US | disclosed |
| US-9005903-B2 | Immunomodulating compositions and methods of use thereof | IMMUNEXCITE, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8945555-B2 | Inotropic antibodies and therapeutic uses thereof | XU KAI YUAN (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2814472-A1 | DITHIOAMINE REDUCING AGENTS | Wisconsin Alumni Research Foundation (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140335536-A1 | VACCINE FOR THE TREATMENT OF MYCOBATERIUM RELATED DISORDERS | MARFL AB (SE) | 2014-11-13 | — | — | US | disclosed |
| US-20140308238-A1 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF | IMMUNEXCITE, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140302046-A1 | Immunological Targeting of Pathological Tau Proteins | NEW YORK UNIVERSITY (US) | 2014-10-09 | — | — | US | disclosed |
| EP-2363488-B1 | Postweaning multisystemic wasting syndrome virus from pigs | MERIAL SAS (FR) | 2014-10-08 | — | — | EP | disclosed |
| US-20140227274-A1 | Prevention and Treatment of Amyloidogenic Disease | JANSSEN ALZHEIMER IMMUNOTHERAPY (IE) | 2014-08-14 | — | — | US | disclosed |
| US-8779088-B2 | Vaccine for the treatment of Mycobacterium related disorders | MARFL AB (SE) | 2014-07-15 | — | — | US | disclosed |
| US-20140162906-A1 | Pesticide Biomarker | NAGY JON OWEN (US) | 2014-06-12 | — | — | US | disclosed |
| US-8741264-B2 | Self-sterilizing products | MOLTENI THERAPEUTICS S.R.L. (IT) | 2014-06-03 | — | — | US | disclosed |
| US-8709731-B2 | DKK1 oncogene as therapeutic target for cancer and a diagnosing marker | ONCOTHERAPY SCIENCE, INC. (JP) | 2014-04-29 | — | — | US | disclosed |
| US-8653240-B2 | Thiosulfonate compound, reversible cationization agent for protein and/or peptide, and method for solubilization | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20140030277-A1 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE (US) | 2014-01-30 | — | — | US | disclosed |
| US-8636981-B2 | Detection of amyloid deposits using anti-amyloid antibodies | ONCLAVE THERAPEUTICS (IE) | 2014-01-28 | — | — | US | disclosed |
| WO-2014013473-A1 | NANOCONSTRUCTS WITH PHARMACOLOGICAL ACTIVITY | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2014-01-23 | — | — | WO | disclosed |
| US-8617823-B2 | Immunomodulating compositions and methods of use thereof | IMMUNEXCITE, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130344566-A1 | Inotropic Antibodies And Therapeutic Uses Thereof | XU KAI YUAN (US) | 2013-12-26 | — | — | US | disclosed |
| EP-1486561-B1 | PROBE MEDIUM | CANON KK (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-8580253-B2 | Immunomodulating compositions and methods of use | WHITEHEAD INSTITUTE (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130230918-A1 | NOVEL COLLECTIN | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2013-09-05 | — | — | US | disclosed |
| WO-2013123382-A1 | DITHIOAMINE REDUCING AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20130211055-A1 | DITHIOAMINE REDUCING AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130202680-A1 | PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE BY AMYLOID BETA PEPTIDE AND SPHIN-GOSINE-1-PHOSPHATE | EUROESPES BIOTECNOLOGÍA, S.L (ES) | 2013-08-08 | — | — | US | disclosed |
| US-20130196433-A1 | Boronate-Mediated Delivery of Molecules into Cells | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2013-08-01 | — | — | US | disclosed |
| WO-2013110005-A1 | BORONATE-MEDIATED DELIVERY OF MOLECULES INTO CELLS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-07-25 | — | — | WO | disclosed |
| US-8440185-B2 | Herpesvirus entry mediator (HVEM) specific immunoglobulin for use in treatment and prevention of transplant rejection, graft-versus-host and transplant autoimmune diseases | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-05-14 | — | — | US | disclosed |
| EP-1923402-B1 | METHOD FOR DETERMINATION OF ENZYMATIC ACTIVITY | SEIKAGAKU KOGYO CO LTD (JP) | 2013-05-08 | — | — | EP | disclosed |
| US-20130096278-A1 | THIOSULFONATE COMPOUND, REVERSIBLE CATIONIZATION AGENT FOR PROTEIN AND/OR PEPTIDE, AND METHOD FOR SOLUBILIZATION | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2013-04-18 | — | — | US | disclosed |
| EP-2066294-B9 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF | WHITEHEAD BIOMEDICAL INST (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8415324-B2 | Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions | JENNY JA ANTTI WIHURIN RAHASTO (FI) | 2013-04-09 | — | — | US | disclosed |
| EP-1904109-B1 | SELF-STERILIZING PRODUCTS | MOLTENI & C (IT) | 2013-04-03 | — | — | EP | disclosed |
| US-20130072447-A1 | ENHANCED ORAL TRANSCOMPARTMENTAL DELIVERY OF THERAPEUTIC OR DIAGANOSTIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130058869-A1 | Prevention And Treatment Of Amyloidogenic Disease | JANSSEN ALZHEIMER IMMUNOTHERAPY (IE) | 2013-03-07 | — | — | US | disclosed |
| US-8383111-B2 | Inotropic antibodies and therapeutic uses thereof | XU KAI Y (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2551263-A1 | THIOSULFONATE COMPOUND, REVERSIBLY CATIONIZING AGENT FOR PROTEINS AND/OR PEPTIDES, AND METHOD FOR SOLUBILIZATION | National University Corporation Okayama University (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-20120276116-A1 | Prevention and Treatment of Amyloidogenic Disease | JANSSEN ALZHEIMER IMMUNOTHERAPY (IE) | 2012-11-01 | — | — | US | disclosed |
| EP-2066294-B1 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF | WHITEHEAD BIOMEDICAL INST (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20120189624-A1 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | ELAN PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120142902-A1 | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-07 | — | — | US | disclosed |
| US-8158365-B2 | Anti-2-O-desulfated acharan sulfate antibody and its application | SEIKAGAKU CORPORATION (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8148136-B1 | Diagnostics and vaccines for mycobacterial infections of animals and humans | HAV VACCINES LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| EP-1852441-B1 | Agents that modulate EPH receptor activity | BURNHAM INST (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120039926-A1 | Compositions and Methods for Modulating Immunogenic Responses by Activating Dendritic Cells | CEL-SCI CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110318826-A1 | INOTROPIC ANTIBODIES AND THERAPEUTIC USES THEREOF | XU KAI Y (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110306756-A1 | Prevention and Treatment of Amyloidogenic Disease | JANSSEN ALZHEIMER IMMUNOTHERAPY (IE) | 2011-12-15 | — | — | US | disclosed |
| US-20110287049-A1 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2363488-A1 | Postweaning multisystemic wasting syndrome virus from pigs | MERIAL (FR) | 2011-09-07 | — | — | EP | disclosed |
| WO-2011102901-A1 | PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE BY AMYLOID BETA PEPTIDE AND SPHINGOSINE-1-PHOSPHATE | EBIOTEC (EUROESPES BIOTECHNOLOGY) (ES) | 2011-08-25 | — | — | WO | disclosed |
| US-20110195073-A1 | COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE | THE JOHNS HOPKINS UNIVERSITY | 2011-08-11 | — | — | US | disclosed |
| US-20110177532-A1 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF | INNATE BIOTHERAPEUTICS, LLC | 2011-07-21 | — | — | US | disclosed |
| US-20110166043-A1 | BIOMARKER DETECTION-2 | ATERIS TECHNOLOGIES, LLC | 2011-07-07 | — | — | US | disclosed |
| US-7964415-B2 | Stable water-soluble polyethylenimine conjugates and methods of use thereof | CARDIOGENICS INC. (CA) | 2011-06-21 | — | — | US | disclosed |
| US-20110104180-A1 | NEW VACCINE FOR THE TREATMENT OF MYCOBACTERIUM RELATED DISORDERS | MARFL AB (SE) | 2011-05-05 | — | — | US | disclosed |
| US-20110098444-A1 | METHODS OF PREPARATION AND COMPOSITION OF PEPTIDE CONSTRUCTS USEFUL FOR TREATMENT OF RHEUMATOID ARTHRITIS | CEL-SCI CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110087004-A1 | ENHANCED ORAL TRANSCOMPARTMENTAL DELIVERY OF THERAPEUTIC OR DIAGNOSTIC AGENTS | RAMANATHAN SRINIVASAN | 2011-04-14 | — | — | US | disclosed |
| US-7919088-B2 | Using alpha-synuclein specific monoclonal antibody to diagnose, prevent amd treat parkinson's disease | ELAN PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110076280-A1 | DKK1 ONCOGENE AS THERAPEUTIC TARGET FOR CANCER AND A DIAGNOSING MARKER | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-03-31 | — | — | US | disclosed |
| US-7915389-B2 | Anti-acharan sulfate antibody and its application | SEIKAGAKU CORPORATION (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20110065177-A1 | Novel Collectin | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110064729-A1 | ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION | ELAN PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110045049-A1 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-24 | — | — | US | disclosed |
| EP-2283358-A2 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF | Immunexcite, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-1132475-B1 | NOVEL SERINE PROTEASE BSSP2 | FUSO PHARMACEUTICAL IND (JP) | 2011-01-19 | — | — | EP | disclosed |
| EP-1958963-B1 | Oxygen-carrying blood substitute preparations | NIPRO CORP (JP) | 2011-01-05 | — | — | EP | disclosed |
| EP-2254588-A2 | METHODS OF PREPARATION AND COMPOSITION OF PEPTIDE CONSTRUCTS USEFUL FOR TREATMENT OF RHEUMATOID ARTHRITIS | Cel-Sci Corporation (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7833783-B2 | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | MERIAL SAS (FR) | 2010-11-16 | — | — | US | disclosed |
| US-20100285997-A1 | PROBE MEDIUM | CANON KABUSHIKI KAISHA (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-1841790-B1 | EPHB RECEPTOR-BINDING PEPTIDES | BURNHAM INST (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010120897-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNOGENIC RESPONSES BY ACTIVATING DENDRITIC CELLS | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2010-10-21 | — | — | WO | disclosed |
| US-7803926-B2 | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | MERIAL SAS (FR) | 2010-09-28 | — | — | US | disclosed |
| US-7803613-B2 | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | MERIAL SAS (FR) | 2010-09-28 | — | — | US | disclosed |
| US-7790366-B1 | NANBV diagnostics and vaccines | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7786119-B2 | Drug conjugates of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2010-08-31 | — | — | US | disclosed |
| US-7754210-B2 | Inotropic antibodies and therapeutic uses thereof | UNIVERSITY OF MARYLAND, BALTIMORE | 2010-07-13 | — | — | US | disclosed |
| US-7741039-B2 | isolation and characterization of new porcine circovirus (PCV) isolates from pigs displaying postweaning multisystemic wasting syndrome (PMWS). | MERIAL SAS (FR) | 2010-06-22 | — | — | US | disclosed |
| US-20100145298-A1 | OXYGEN-CARRYING BLOOD SUBSTITUTE PREPARATIONS | HORI NOBUAKI | 2010-06-10 | — | — | US | disclosed |
| US-20100041077-A1 | PESTICIDE BIOMARKER | ATERIS TECHNOLOGIES, LLC | 2010-02-18 | — | — | US | disclosed |
| EP-1354896-B1 | MONOCLONAL ANTIBODY DIRECTED AGAINST THE HUMAN BST2 ANTIGEN | KYOWA HAKKO KIRIN CO LTD (JP) | 2010-02-10 | — | — | EP | disclosed |
| US-20100015160-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING ENDOMETRIOSIS | YALE UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
| US-20090297511-A1 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE | NEURALAB LIMITED (US) | 2009-12-03 | — | — | US | disclosed |
| EP-1637883-B1 | IMMUNOCHROMATOGRAPHIC METHOD | MITSUBISHI KAGAKU IATRON INC (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090280502-A1 | ANTI-2-O-DESULFATED ACHARAN SULFATE ANTIBODY AND ITS APPLICATION | SEIKAGAKU CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090275048-A1 | ANTI-ACHARAN SULFATE ANTIBODY AND ITS APPLICATION | SEIKAGAKU CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| WO-2009134891-A2 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF | IMMUNEXCITE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| EP-2109455-A2 | COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE | The Johns Hopkins University (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1122543-B1 | Immunoassay for human medullasin and method of diagnosing multiple sclerosis | DAINICHISEIKA COLOR CHEM (JP) | 2009-10-14 | — | — | EP | disclosed |
| US-7592005-B2 | Multiple myeloma; targeting antibody conjugated with a radionuclide or other cytotoxic substance | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-09-22 | — | — | US | disclosed |
| WO-2009114869-A2 | METHODS OF PREPARATION AND COMPOSITION OF PEPTIDE CONSTRUCTS USEFUL FOR TREATMENT OF RHEUMATOID ARTHRITIS | CEL-SCI CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090208487-A1 | Prevention and treatment of synucleinopathic and amyloidogenic disease | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090202607-A1 | HEPARIN-LIKE COMPOUNDS, THEIR PREPARATION AND USE TO PREVENT ARTERIAL THROMBOSIS ASSOCIATED WITH VASCULAR INJURY AND INTERVENTIONS | JENNY JA ANTTI WIHURIN RAHASTO (FI) | 2009-08-13 | — | — | US | disclosed |
| EP-1142993-B1 | METHOD FOR DETECTING PANCREATITIS | FUSO PHARMACEUTICAL IND (JP) | 2009-08-05 | — | — | EP | disclosed |
| EP-0419182-B2 | New HCV isolate J-1 | OYA AKIRA DR DIRECTOR GENERAL (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-20090169549-A1 | CONFORMATIONAL ISOMERS OF ALPHA-SYNUCLEIN, ANTIBODIES THERETO AND METHODS OF THEIR MANUFACTURE AND USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-07-02 | — | — | US | disclosed |
| WO-2009077438-A1 | METHOD FOR PREPARING PROTEIN CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2009-06-25 | — | — | WO | disclosed |
| EP-1578450-A4 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2009-06-17 | — | — | EP | disclosed |
| EP-2066294-A2 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF | Whitehead Institute (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2009065181-A1 | NANOSTRUCTURES SUITABLE FOR DELIVERY OF AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2009-05-28 | — | — | WO | disclosed |
| US-20090130049-A1 | Self-Sterilizing Products | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO S.P.A. (IT) | 2009-05-21 | — | — | US | disclosed |
| US-20090104627-A1 | METHOD FOR DETERMINATION OF ENZYMATIC ACTIVITY | SEIKAGAKU CORPORATION (JP) | 2009-04-23 | — | — | US | disclosed |
| US-7504206-B2 | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | MERIAL SAS (FR) | 2009-03-17 | — | — | US | disclosed |
| US-20090028847-A1 | MULTIPLE MYELOMA AND AL AMYLOID IMMUNOTHERAPY TARGETING IMMUNOGLOBULIN LIGHT CHAINS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-01-29 | — | — | US | disclosed |
| EP-2018399-A1 | ANTI-2-O-DESULFATED ACHARAN SULFATE ANTIBODY AND ITS APPLICATION | SEIKAGAKU CORPORATION (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-2018398-A1 | ANTI-ACHARAN SULFATE ANTIBODY AND ITS APPLICATION | SEIKAGAKU CORPORATION (JP) | 2009-01-28 | — | — | EP | disclosed |
| US-20080233181-A1 | NANOPARTICLE ADJUVANTS FOR SUB-UNIT VACCINES | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2008-09-25 | — | — | US | disclosed |
| US-20080206235-A1 | COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE | JOHNS HOPKINS UNIVERSITY | 2008-08-28 | — | — | US | disclosed |
| EP-1958963-A1 | Oxygen-carrying blood substitute preparations | Nipro Corporation (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-20080193516-A1 | OXYGEN-CARRYING BLOOD SUBSTITUTE PREPARATIONS | NIPRO CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080187542-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOLOGIC DISORDERS | JOHNS HOPKINS UNIVERSITY | 2008-08-07 | — | — | US | disclosed |
| US-20080175838-A1 | Prevention And Treatment of Synucleinopathic And Amyloidogenic Disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| WO-2008057501-A9 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF | WHITEHEAD BIOMEDICAL INST (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008083239-A2 | COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1161262-B1 | SURFACE LOCALIZED COLLIGIN/HsP47 IN CARCINOMA CELLS | UNIV MARYLAND (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1923402-A1 | METHOD FOR DETERMINATION OF ENZYMATIC ACTIVITY | SEIKAGAKU CORPORATION (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2008057501-A2 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE (US) | 2008-05-15 | — | — | WO | disclosed |
| US-7371386-B2 | Conserved motif of hepatitis C virus E2/NS1 region | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1916260-A1 | Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions | Jenny Ja Antti Wihurin Rahasto (FI) | 2008-04-30 | — | — | EP | disclosed |
| US-7358061-B2 | Methods of diagnosing thyroid carcinoma | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| EP-1904109-A1 | SELF-STERILIZING PRODUCTS | L. Molteni&c. dei Fratelli Alitti Societa' di Eserss (IT) | 2008-04-02 | — | — | EP | disclosed |
| US-20080069867-A1 | Diagnostic and/or Remedy for Ovarian Cancer | MITSUBISHI PHARMA CORPORATION (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1687450-A4 | REAL-TIME DETECTION OF NUCLEIC ACIDS AND PROTEINS | HAN MYUN KI (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20080021005-A1 | Pegylated Ion Channel Modulating Compounds | CARDIOME PHARMA CORP. (CA) | 2008-01-24 | — | — | US | disclosed |
| EP-1871884-A2 | PORCINE CIRCOVIRUS AND HELICOBACTER COMBINATION VACCINES | Merial Ltd. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-7314860-B2 | Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions | JENNY JA ANTTI WILHURIN RAHASTO (FI) | 2008-01-01 | — | — | US | disclosed |
| US-7312040-B2 | Microcapsule biosensors and methods of using the same | AGILENT TECHNOLOGIES, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007131286-A1 | NANOSTRUCTURES SUITABLE FOR DELIVERY OF AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-11-22 | — | — | WO | disclosed |
| EP-1034189-B1 | HEPARIN-LIKE COMPOUNDS, THEIR PREPARATION AND USE TO PREVENT ARTERIAL THROMBOSIS ASSOCIATED WITH VASCULAR INJURY AND INTERVENTIONS | JENNY JA ANTTI WIHURIN RAHASTO (FI) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007126155-A1 | ANTI-2-O-DESULFATED ACHARAN SULFATE ANTIBODY AND ITS APPLICATION | SEIKAGAKU CORPORATION (JP) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007126152-A1 | ANTI-ACHARAN SULFATE ANTIBODY AND ITS APPLICATION | SEIKAGAKU CORPORATION (JP) | 2007-11-08 | — | — | WO | disclosed |
| EP-1852441-A2 | Agents that modulate EPH receptor activity | The Burnham Institute (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070254285-A1 | Stable water-soluble polyethylenimine conjugates and methods of use thereof | CARDIOGENICS INC. (CA) | 2007-11-01 | — | — | US | disclosed |
| US-7285289-B2 | Nanoparticle vaccines | NANOVALENT PHARMACEUTICALS, INC. | 2007-10-23 | — | — | US | disclosed |
| US-7282579-B2 | Serine protease BSSP6 | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2007-10-16 | — | — | US | disclosed |
| EP-1841790-A2 | EPHB RECEPTOR-BINDING PEPTIDES | The Burnham Institute (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1129724-B1 | Vaccines for treating colon cancer | UNIV OHIO STATE RES FOUND (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070202099-A1 | Antibody Drug | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-30 | — | — | US | disclosed |
| EP-1816200-A1 | Postweaning multisystemic wasting syndrome virus for pigs | MERIAL (FR) | 2007-08-08 | — | — | EP | disclosed |
| EP-1092772-B1 | ANTIBODY AGAINST LAR PHOSPHATASE SUBUNIT | FUSO PHARMACEUTICAL IND (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-7252827-B1 | Conserved motif of hepatitis C virus E2/NS1 region | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1037909-B1 | POSTWEANING MULTISYSTEMIC WASTING SYNDROME VIRUS FROM PIGS | UNIV SASKATCHEWAN (CA) | 2007-06-13 | — | — | EP | disclosed |
| US-7214500-B2 | Brush-like structured surface of poly(ethylene oxide) having elevated density | TOUDAI TLO, LTD. (JP) | 2007-05-08 | — | — | US | disclosed |
| US-20070099181-A1 | isolation and characterization of new porcine circovirus (PCV) isolates from pigs displaying postweaning multisystemic wasting syndrome (PMWS). | MERIAL SAS | 2007-05-03 | — | — | US | disclosed |
| US-7211425-B2 | Obtained by cloning of cDNA encoding novel human and mouse serine proteases | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7192594-B2 | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | MERIAL LIMITED (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070059318-A1 | Lipid nano particulates containing antigens as cancer vaccines | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2007-03-15 | — | — | US | disclosed |
| WO-2007022152-A2 | LIPID NANO PARTICULATES CONTAINING ANTIGENS AS CANCER VACCINES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070020729-A1 | Novel collectin | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20070014813-A1 | Conserved motif of hepatitis C virus E2/NS1 region | CHIRON CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070009550-A1 | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2007-01-11 | — | — | US | disclosed |
| WO-2007000472-A1 | SELF-STERILIZING PRODUCTS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO S.P.A. (IT) | 2007-01-04 | — | — | WO | disclosed |
| US-20060292177-A1 | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2006-12-28 | — | — | US | disclosed |
| US-20060292556-A1 | Method of detecting antibodies to HCV | CHIRON CORPORATION (US) | 2006-12-28 | — | — | US | disclosed |
| US-20060286679-A1 | Immunochromatographic method | MITSUBISHI KAGAKU LATRON, INC. (JP) | 2006-12-21 | — | — | US | disclosed |
| US-20060286642-A1 | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2006-12-21 | — | — | US | disclosed |
| EP-1108786-B1 | NOVEL COLLECTIN | FUSO PHARMACEUTICAL IND (JP) | 2006-12-13 | — | — | EP | disclosed |
| EP-1731168-A1 | ANTIBODY DRUG | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
| US-7135185-B1 | Conserved motif of hepatitis C virus E2/NS1 region | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060239994-A1 | Novel serine protease BSSP4 | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006113372-A2 | PORCINE CIRCOVIRUS AND HELICOBACTER COMBINATION VACCINES | MERIAL LIMITED (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060233789-A1 | Process for producing antigenic substance | CELLFREE SCIENCE CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| US-7112654-B2 | Ligand for vascular endothelial growth factor receptor | SUPRATEK PHARMA INC. (CA) | 2006-09-26 | — | — | US | disclosed |
| US-7098303-B1 | Conserved motif of hepatitis C virus E2/NS1 region | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1687450-A2 | REAL-TIME DETECTION OF NUCLEIC ACIDS AND PROTEINS | Han, Myun Ki (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006081418-A2 | EPHB RECEPTOR-BINDING PEPTIDES | THE BURNHAM INSTITUTE (US) | 2006-08-03 | — | — | WO | disclosed |
| US-7081348-B2 | Immunoassay of human medullasin and diagnosis of multiple sclerosis using the same | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2006-07-25 | — | — | US | disclosed |
| US-20060134610-A1 | Chris-like virus, compositions, vaccines and uses thereof | PALESE PETER M | 2006-06-22 | — | — | US | disclosed |
| US-20060127310-A1 | Amplification of biotin-mediated targeting | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD. | 2006-06-15 | — | — | US | disclosed |
| EP-1669448-A1 | PROCESS FOR PRODUCING ANTIGENIC SUBSTANCE | CellFree Sciences Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20060121038-A9 | Prevention and treatment of amyloidogenic disease | NEURALAB LIMITED (BM) | 2006-06-08 | — | — | US | disclosed |
| US-20060105396-A1 | Novel epithelial tissue imaging agent | PLANTIBODIES CORPORATION (US) | 2006-05-18 | — | — | US | disclosed |
| EP-1521849-A4 | HEPATITIS A VIRUS NUCLEOTIDE SEQUENCES, RECOMBINANT PROTEINS AND USES THEREOF | CHIRON CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1553963-A4 | NOVEL AGENTS THAT MODULATE EPH RECEPTOR ACTIVITY | BURNHAM INST (US) | 2006-05-03 | — | — | EP | disclosed |
| US-7022309-B2 | Targeting molecule linked to an imaging agent | BIOLEX NEWCO I, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1637883-A1 | IMMUNOCHROMATOGRAPHIC METHOD | Mitsubishi Kagaku Iatron, Inc. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-6998245-B1 | Serine protease BSSP5 | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20060029617-A1 | Porcine circovirus and Helicobacter combination vaccines and methods of use | MERIAL LIMITED | 2006-02-09 | — | — | US | disclosed |
| US-20060002941-A1 | Compositions comprising immune response altering agents and methods of use | VIEVAX CORP. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20060002952-A1 | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | Merial Limited; University of Saskatchewan | 2006-01-05 | — | — | US | disclosed |
| WO-2005090570-A9 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING DISEASES THAT INVOLVE ANGIOGENESIS | SUPRATEK PHARMA INC (CA) | 2005-12-15 | — | — | WO | disclosed |
| US-20050277575-A1 | Therapeutic compositions and methods for treating diseases that involve angiogenesis | SEMOV ALEXANDRE | 2005-12-15 | — | — | US | disclosed |
| US-20050255122-A1 | Prevention and treatment of amyloidogenic disease | NEURALAB LIMITED (BM) | 2005-11-17 | — | — | US | disclosed |
| EP-0388232-B9 | NANBV diagnostics and vaccines | CHIRON CORP (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6953567-B2 | Fluorination of proteins and peptides for F-18 positron emission tomography | IMMUNOMEDICS, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6951647-B2 | T cell binding ligand peptides and method of inducing a cellular immune response | CEL-SCI CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050214809-A1 | Real-time detection of nucleic acids and proteins | HAN MYUN K | 2005-09-29 | — | — | US | disclosed |
| EP-1578450-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | Access Pharmaceuticals Australia Pty Ltd (AU) | 2005-09-28 | — | — | EP | disclosed |
| WO-2005086775-A2 | LUMEN-EXPOSED MOLECULES AND METHODS FOR TARGETED DELIVERY | UTAH VENTURES II, L.P. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050202418-A1 | HCV peptide compositions | HOUGHTON MICHAEL (US) | 2005-09-15 | — | — | US | disclosed |
| US-6942965-B2 | Hepatitis A virus nucleotide sequences, recombinant proteins and uses thereof | CHIRON CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2005070959-A2 | COMPOSITIONS COMPRISING IMMUNE RESPONSE ALTERING AGENTS AND METHODS OF USE | VIEVAX CORP. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050170415-A1 | Serine protease BSSP6 | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| US-20050163788-A1 | administering an A beta peptide and a 3 De-O-acylated monophosphoryl lipid A (MPL) adjuvant to induce an immune response comprising antibodies to the A beta peptide | NEURALAB LIMITED (BM) | 2005-07-28 | — | — | US | disclosed |
| US-20050165223-A1 | Immunoglobulin for use in diagnosis, prevention and treatment of nervous system and neurodegenerative disorders | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2005-07-28 | — | — | US | disclosed |
| US-6921658-B1 | Serine protease BSSP6 | FUSO PHARMACUTICAL INDUSTRIES, LTD. (JP) | 2005-07-26 | — | — | US | disclosed |
| US-20050158304-A1 | Prevention and treatment of amyloidogenic disease | NEURALAB LIMITED (BM) | 2005-07-21 | — | — | US | disclosed |
| EP-1553963-A1 | NOVEL AGENTS THAT MODULATE EPH RECEPTOR ACTIVITY | The Burnham Institute (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20050142028-A1 | Brush-like structured surface of poly(ethylene oxide) having elevated density | TOUDAI TLO, LTD. (JP) | 2005-06-30 | — | — | US | disclosed |
| US-6908756-B1 | Serine protease BSSP2 | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| US-20050130135-A1 | Hepatitis a virus nucleotide sequences, recombinant proteins and uses thereof | CHIRON CORPORATION | 2005-06-16 | — | — | US | disclosed |
| WO-2005052127-A2 | REAL-TIME DETECTION OF NUCLEIC ACIDS AND PROTEINS | HAN MYUN KI (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050123544-A1 | Prevention and treatment of amyloidogenic disease | NEURALAB LIMITED (BM) | 2005-06-09 | — | — | US | disclosed |
| WO-2005046731-A1 | INTERFERENCE WITH C-MAF FUNCTION IN MULTIPLE MYELOMA | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050106570-A1 | Adsorption of impurities is inhibited; semiconductors, for genetic replication; competitive binding | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2005-05-19 | — | — | US | disclosed |
| US-6890535-B1 | Pharmaceutical compositions and methods for treatment of amyloid diseases | NEURALAB LIMITED (BM) | 2005-05-10 | — | — | US | disclosed |
| EP-1521849-A2 | HEPATITIS A VIRUS NUCLEOTIDE SEQUENCES, RECOMBINANT PROTEINS AND USES THEREOF | CHIRON CORPORATION (US) | 2005-04-13 | — | — | EP | disclosed |
| EP-0794434-B1 | METHOD FOR THE ANALYSIS OF ALLERGEN | ASAHI DENKA KOGYO KK (JP) | 2005-04-06 | — | — | EP | disclosed |
| US-20050059591-A1 | Prevention and treatment of amyloidogenic disease | NEURALAB LIMITED (BM) | 2005-03-17 | — | — | US | disclosed |
| US-6866849-B2 | Prevention and treatment of amyloidogenic disease | NEURALAB LIMITED (BM) | 2005-03-15 | — | — | US | disclosed |
| US-6866850-B2 | Prevention and treatment of amyloidogenic disease | NEURALAB LIMITED (BM) | 2005-03-15 | — | — | US | disclosed |
| US-20050053983-A1 | Human protease for use in identifying modulators for treatment and prevention of nervous system and psychological disorders | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| US-6861212-B1 | NANBV diagnostics and vaccines | CHIRON CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-20050042222-A1 | Methods of diagnosing thyroid carcinoma | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20050037026-A1 | such as Alzheimer's disease; amyloid precursor proteins; comprises diphtheria toxoid as carrier | NEURALAB LIMITED (BM) | 2005-02-17 | — | — | US | disclosed |
| US-20050026232-A1 | Antibodies specific for phosphatase subunit of LAR | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2005-02-03 | — | — | US | disclosed |
| WO-2005009467-A1 | CHRIS-LIKE VIRUS, COMPOSITIONS, VACCINES AND USES THEREOF | PALESE PETER (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050019957-A1 | Immunoassay of human medullasin and diagnosis of multiple sclerosis using the same | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. | 2005-01-27 | — | — | US | disclosed |
| US-6846912-B1 | Antibody against LAR phosphatase subunit | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| EP-1311548-A4 | T CELL BINDING LIGAND PEPTIDES, PEPTIDE CONSTRUCTS CONTAINING SAME AND USE THEREOF FOR TREATMENT OF IMMUNOLOGICAL DISORDERS | CEL SCI CORP (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20050008645-A1 | Antibodies Specific For Phosphatase Subunit of LAR | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1496363-A1 | BIOCHIP SENSOR SURFACE CARRYING POLYETHYLENE GLYCOLATED NANOPARTICLES | Japan Science and Technology Agency (JP) | 2005-01-12 | — | — | EP | disclosed |
| EP-0388232-B1 | NANBV diagnostics and vaccines | CHIRON CORP (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040266694-A1 | Ligand for vascular endothelial growth factor receptor | SUPRATEK PHARMA INC. (CA) | 2004-12-30 | — | — | US | disclosed |
| EP-1489415-A1 | BRUSH-LIKE STRUCTURED SURFACE OF POLY(ETHYLENE OXIDE) HAVING ELEVATED DENSITY | TOUDAI TLO, Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
| EP-1399215-A4 | TISSUE-SPECIFIC ENDOTHELIAL MEMBRANE PROTEINS | UTAH VENTURES II L P (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1486561-A1 | PROBE MEDIUM | Canon Kabushiki Kaisha (JP) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004106522-A1 | GENE ENCODING A RIBOSOME-INACTIVATING PROTEIN, KNOWN AS RECOMBINANT MUSARMIN 4, EXPRESSION IN BACTERIAL SYSTEM, METHOD OF OBTAINING SAME AND APPLICATIONS THEREOF | UNIVERSIDAD DE VALLADOLID (ES) | 2004-12-09 | — | — | WO | disclosed |
| EP-0745129-B1 | NON-A, NON-B, NON-C, NON-D, NON-E HEPATITIS REAGENTS AND METHODS FOR THEIR USE | ABBOTT LAB (US) | 2004-11-24 | — | — | EP | disclosed |
| US-6818218-B2 | BETA AMYLOID PEPTIDE AND ENHANCER | NEURALAB LIMITED (BM) | 2004-11-16 | — | — | US | disclosed |
| US-20040219146-A1 | administering an antibody that binds amyloid beta peptide to treat Alzheimer's disease, SAA amyloidosis, hereditary Icelandic syndrome, multiple myeloma, mad cow and Creutzfeldt Jakob disease, sheep scrapie, mink spongiform encephalopathy, mild cognitive impairment, or AD associated with Down's syndrome | NEURALAB LIMITED (BM) | 2004-11-04 | — | — | US | disclosed |
| EP-1460132-A1 | Antibodies with specific immunoreactivity to thyroid carcinoma cells | FUSO PHARMACEUTICAL INDUSTRIES LTD. (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6787140-B1 | Prevention and treatment of amyloidogenic disease | NEURALAB LIMITED (BM) | 2004-09-07 | — | — | US | disclosed |
| US-20040166119-A1 | Prevention and treatment of amyloidogenic disease | NEURALAB LIMITED (BM) | 2004-08-26 | — | — | US | disclosed |
| US-20040157779-A1 | Prevention and treatment of amyloidogenic disease | NEURALAB LIMITED (BM) | 2004-08-12 | — | — | US | disclosed |
| US-20040146521-A1 | Prevention and treatment of synucleinopathic disease | CRIMAGUA LIMITED (IE) | 2004-07-29 | — | — | US | disclosed |
| US-6767709-B1 | A METHOD OF IMMUNOLOGICALLY MEASURING HUMAN MEDULLASIN IN BLOOD INCLUDING A STEP OF PRETREATING THE BLOOD SAMPLE IN ORDER TO ACCURATELY MEASURE THE CONTENT OF MEDULLASIN IN THE GRANULOCYTES IN THE BLOOD | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2004-07-27 | — | — | US | disclosed |
| US-6764827-B1 | Anti-human medullasin monoclonal antibody process for producing the same and immunoassay using the same | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2004-07-20 | — | — | US | disclosed |
| US-20040136982-A1 | Novel monoclonal antibody | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-0745128-B8 | HEPATITIS B VIRUS MUTANTS, REAGENTS AND METHODS FOR DETECTION | ABBOTT LAB (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040132178-A1 | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | MERIAL SAS (FR) | 2004-07-08 | — | — | US | disclosed |
| WO-2004028551-A9 | NOVEL AGENTS THAT MODULATE EPH RECEPTOR ACTIVITY | BURNHAM INST (US) | 2004-07-01 | — | — | WO | disclosed |
| EP-1206251-A4 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2004-06-30 | — | — | EP | disclosed |
| US-20040109871-A1 | M cell directed vaccines | MONTANA STATE UNIVERSITY | 2004-06-10 | — | — | US | disclosed |
| WO-2004045647-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2004-06-03 | — | — | WO | disclosed |
| US-6743427-B1 | ADMINISTERING TO PATIENT EFFECTIVE DOSAGE OF PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY THAT SPECIFICALLY BINDS TO EPITOPE WITHIN RESIDUES 1-12 OF BETA-AMYLOID WHEREIN ISOTYPE OF ANTIBODY IS HUMAN IMMUNOGLOBULIN-G1 | NEURALAB LIMITED (BM) | 2004-06-01 | — | — | US | disclosed |
| EP-1421951-A2 | Conserved motif of hepatitis C virus E2/NS1 region | CHIRON CORPORATION (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040091851-A1 | HCV peptide compositions | HOUGHTON MICHAEL (US) | 2004-05-13 | — | — | US | disclosed |
| US-6720166-B2 | NUCLEOTIDE SEQUENCES FOR USE IN THE DETECTION, PREVENTION AND TREATMENT OF VIRAL INFECTIONS | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| WO-2004028551-A1 | NOVEL AGENTS THAT MODULATE EPH RECEPTOR ACTIVITY | THE BURNHAM INSTITUTE (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040057968-A1 | T cell binding ligand peptides, peptide constructs containing same and use thereof for treatment of immunological disorders | ZIMMERMAN DANIEL H (US) | 2004-03-25 | — | — | US | disclosed |
| US-20040057956-A1 | Inotropic antibodies and therapeutic uses thereof | UNIVERSITY OF MARYLAND, BALTIMORE | 2004-03-25 | — | — | US | disclosed |
| US-20040058381-A1 | Microcapsule biosensors and methods of using the same | AGILENT TECHNOLOGIES, INC. | 2004-03-25 | — | — | US | disclosed |
| EP-1399215-A2 | TISSUE-SPECIFIC ENDOTHELIAL MEMBRANE PROTEINS | UTAH VENTURES II, L.P. (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1394256-A2 | HCV genomic sequences for diagnostics and therapeutics | Chiron Corporation (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1394255-A2 | NANBV diagnostics and vaccines | CHIRON CORPORATION (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6696274-B2 | POLYPEPTIDES CAPABLE OF CROSSING THE SMALL INTESTINE OR BLOOD BRAIN BARRIER; BIOAVAILABILITY | SUPRATEK PHARMA, INC. (CA) | 2004-02-24 | — | — | US | disclosed |
| US-20040033584-A1 | Therapeutic use of particles displaying pathogen-specific binding moieties | ELUSYS THERAPEUTICS, INC. | 2004-02-19 | — | — | US | disclosed |
| US-6692907-B1 | NEWLY DISCOVERED MOTIF WITHIN THIS HYPERVARIABLE REGION IS IMMUNOGENIC AND CONSERVED WITH RESPECT TO THE CHARACTER OF THE AMINO ACIDS | CHIRON CORPORATION | 2004-02-17 | — | — | US | disclosed |
| US-20040022840-A1 | Nanoparticle vaccines | NANOVALENT PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| EP-1385873-A2 | A LIGAND FOR ENHANCING ORAL AND CNS DELIVERY OF BIOLOGICAL AGENTS | SUPRATEK PHARMA, INC. (CA) | 2004-02-04 | — | — | EP | disclosed |
| US-20040005620-A1 | Probe medium | CANON KABUSHIKI KAISHA (JP) | 2004-01-08 | — | — | US | disclosed |
| US-20030232328-A1 | Method of detecting antibodies to HCV | HOUGHTON MICHAEL (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030224443-A1 | Novel epithelial tissue imaging agent | EPICYTE PHARMACEUTICAL, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030211467-A1 | Methods and compositions for detecting hepatitis E virus | SCHLAUDER GEORGE G (US) | 2003-11-13 | — | — | US | disclosed |
| US-20030212042-A1 | Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions | JENNY JA ANTTI WIHURIN RAHASTO (FI) | 2003-11-13 | — | — | US | disclosed |
| EP-0745128-B1 | HEPATITIS B VIRUS MUTANTS, REAGENTS AND METHODS FOR DETECTION | ABBOTT LAB (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1354896-A1 | NOVEL MONOCLONAL ANTIBODY | KIRIN BEER KABUSHIKI KAISHA (JP) | 2003-10-22 | — | — | EP | disclosed |
| WO-2003084469-A2 | TISSUE-SPECIFIC ENDOTHELIAL MEMBRANE PROTEINS | UTAH VENTURES II, L.P. (US) | 2003-10-16 | — | — | WO | disclosed |
| EP-0585398-B1 | HCV GENOMIC SEQUENCES FOR DIAGNOSTICS AND THERAPEUTICS | CHIRON CORP (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-0697888-B1 | CONSERVED MOTIF OF HEPATITIS C VIRUS E2/NS1 REGION | CHIRON CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030170616-A1 | Diagnosis using antibodies; genetic engineering | MERIAL SAS (FR) | 2003-09-11 | — | — | US | disclosed |
| US-20030162167-A1 | METHOD OF DETECTING ANTIBODIES TO HCV | CHIRON CORPORATION | 2003-08-28 | — | — | US | disclosed |
| WO-2003066096-A1 | POLYMERIC CONJUGATES FOR DELIVERY OF MHC-RECOGNIZED EPITOPES VIA PEPTIDE VACCINES | VAXIM, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-0609580-B1 | Recombinant CMV neutralising proteins | AVENTIS PASTEUR (FR) | 2003-07-30 | — | — | EP | disclosed |
| US-20030124517-A1 | Hepatitis A virus nucleotide sequences, recombinant proteins and uses thereof | Grifols Therapeutics Inc. | 2003-07-03 | — | — | US | disclosed |
| US-6586568-B1 | Purified viral polypeptide comprising amino acid sequence encoded by positive stranded RNA genome which comprises an open reading frame encoding a polyprotein; use in diagnosing and providing safer blood and organ supply | ABBOTT LABORATORIES | 2003-07-01 | — | — | US | disclosed |
| US-6583266-B1 | Peptide for use in the diagnosis and treatment of skin disorders and tuberculosis | GENOME THERAPEUTICS CORPORATION | 2003-06-24 | — | — | US | disclosed |
| US-6572860-B1 | ICP27, glycoprotein B, ribonucleotide reductase, ICP4, ICP34.5, glycoprotein E or glycoprotein F and an immunomodulatory peptide which is a portion of an immunoprotein which promotes binding to a class of T cells and | CEL-SCI CORPORATION | 2003-06-03 | — | — | US | disclosed |
| EP-1311548-A1 | T CELL BINDING LIGAND PEPTIDES, PEPTIDE CONSTRUCTS CONTAINING SAME AND USE THEREOF FOR TREATMENT OF IMMUNOLOGICAL DISORDERS | Cel-Sci Corporation (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6558898-B1 | Antibody for use in the treatment of viral diseases | ABBOTT LABORATORIES | 2003-05-06 | — | — | US | disclosed |
| WO-2003030624-A2 | HEPATITIS A VIRUS NUCLEOTIDE SEQUENCES, RECOMBINANT PROTEINS AND USES THEREOF | CHIRON CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-0781142-A4 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYPEPTIDES | ALLIED MEDICAL RES ASSOCIATES (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20030050227-A1 | Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-03-13 | — | — | US | disclosed |
| US-20030049253-A1 | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines | VAXIM | 2003-03-13 | — | — | US | disclosed |
| US-20030049601-A1 | METHODS AND COMPOSITIONS FOR DETECTING HEPATITIS E VIRUS | ABOTT LABORATORIES | 2003-03-13 | — | — | US | disclosed |
| US-20030017156-A1 | CONSERVED MOTIF OF HEPATITIS C VIRUS E2/NS1 REGION | CHIRON CORPORATION | 2003-01-23 | — | — | US | disclosed |
| EP-0966296-A4 | CONJUGATED PEPTIDES, IMMUNOLOGICAL REAGENT CONTAINING SAME AND USE THEREOF FOR TREATMENT OF IMMUNOLOGICAL DISORDERS | CEL SCI CORP (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6500800-B1 | Composition and method for causing photodynamic damage to target cells | SOBOLEV ALEXANDER SERGEEVICH (RU) | 2002-12-31 | — | — | US | disclosed |
| WO-2002100336-A2 | TISSUE-SPECIFIC ENDOTHELIAL MEMBRANE PROTEINS | UTAH VENTURES II, L.P. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-0591431-B1 | HEPATITIS C VIRUS (HCV) POLYPEPTIDES | CHIRON CORP (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-0608261-B1 | IMMUNOREACTIVE HEPATITIS C VIRUS POLYPEPTIDE COMPOSITIONS | CHIRON CORP (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-0251575-B2 | Hepatitis delta diagnostics and vaccines, their preparation and use | CHIRON CORP (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-1252177-A1 | LIGAND FOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR | SUPRATEK PHARMA, INC. (CA) | 2002-10-30 | — | — | EP | disclosed |
| EP-1247099-A2 | METHODS AND COMPOSITIONS FOR DETECTING HEPATITIS E VIRUS | ABBOTT LABORATORIES (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020137684-A1 | Ligand for enhancing oral and CNS delivery of biological agents | SUPRATEK PHARMA, INC. (CA) | 2002-09-26 | — | — | US | disclosed |
| WO-2002072015-A2 | M CELL DIRECTED VACCINES | MONTANA STATE UNIVERSITY-BOZEMAN (US) | 2002-09-19 | — | — | WO | disclosed |
| US-6451578-B1 | HEPATITIS, AMINO ACID SEQUENCES AND NUCLEIC ACIDS | ABBOTT LABORATORIES | 2002-09-17 | — | — | US | disclosed |
| US-20020119447-A1 | NON-A,NON-B,NON-C,NON-C,NON-D,NON-E HEPATITIS REAGENTS AND METHODS FOR THEIR USE | ABBOTT LABORATORIES | 2002-08-29 | — | — | US | disclosed |
| US-20020119096-A1 | Fluorination of proteins and peptides for F-18 positron emission tomography | IMMUNOMEDICS, INC. | 2002-08-29 | — | — | US | disclosed |
| EP-1102788-A4 | PREVENTION AND TREATMENT OF VIRAL DISEASE | UNIV MONTANA (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020114816-A1 | AUTOREACTIVE PEPTIDES FROM HUMAN GLUTAMIC ACID-DECARBOXYLASE (GAD) | BOEHRINGER MANNHEIM GMBH (DE) | 2002-08-22 | — | — | US | disclosed |
| US-20020106639-A1 | Nucleotide sequences coding polypeptide for use in vaccination and prevention and treatment of viral infections | UNIVERSITY OF SASKATCHEWAN | 2002-08-08 | — | — | US | disclosed |
| US-20020102562-A1 | Recombinant CMV neutralizing proteins | PASTEUR MERIEUX SERUMS ET VACCINES S.A. | 2002-08-01 | — | — | US | disclosed |
| EP-1206251-A1 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 2002-05-22 | — | — | EP | disclosed |
| US-6391280-B1 | TARGETING MOLECULES FOR USE IN DELIVERY OF IMAGING AGENTS TO EPITHELIAL CELLS | EPICYTE PHARMACEUTICAL, INC. | 2002-05-21 | — | — | US | disclosed |
| US-20020058619-A1 | Ligand for vascular endothelial growth factor receptor | SUPTRATEK PHARMA, INC. (CA) | 2002-05-16 | — | — | US | disclosed |
| US-6358489-B1 | REACTING PEPTIDE COMPRISING A FREE THIOL GROUP WITH A F-18 FLUORINATED ALKENE, WHEREIN AT LEAST ONE OF THE TWO DOUBLE-BONDED CARBON ATOMS BEARS LEAVING GROUP SELECTED FROM IODIDE, BROMIDE, CHLORIDE, AZIDE, TOSYLATE, MESYLATE, NOSYLATE | IMMUNOMEDICS, INC. | 2002-03-19 | — | — | US | disclosed |
| US-6358524-B1 | FOR GENE THERAPY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-03-19 | — | — | US | disclosed |
| US-6346375-B1 | OCTAMER POLYPEPTIDE IMMUNOREACTIVE WITH HEPATITIS C VIRUS ANTIBODY; EPITOPES, IMMUNOGENS; GENE EXPRESSION, GENETIC ENGINEERING | CHIRON CORPORATION | 2002-02-12 | — | — | US | disclosed |
| US-20020016308-A1 | HEPARIN-LIKE COMPOUNDS, THEIR PREPARATION AND USE TO PREVENT ARTERIAL THROMBSIS ASSOCIATED WITH VASCULAR INJURY AND INTERVETIONS | JENNY JA ANTTI WIHURIN RAHASTO (FI) | 2002-02-07 | — | — | US | disclosed |
| WO-2000008043-A9 | PREVENTION AND TREATMENT OF VIRAL DISEASE | UNIV MONTANA (US) | 2001-12-13 | — | — | WO | disclosed |
| EP-0522159-B1 | ANTIBODY TO PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE-PACAP, HYBRIDOMA AND ASSAY FOR PACAP | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-12-12 | — | — | EP | disclosed |
| WO-2001089286-A2 | T CELL BINDING LIGAND PEPTIDES, PEPTIDE CONSTRUCTS CONTAINING SAME AND USE THEREOF FOR TREATMENT OF IMMUNOLOGICAL DISORDERS | CEL-SCI CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090139-A2 | A LIGAND FOR ENHANCING ORAL AND CNS DELIVERY OF BIOLOGICAL AGENTS | SUPRATEK PHARMA INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| US-6303292-B1 | GENETICLLY ENGINEERED VIRAL POLYPEPTIDES; FOR USE IN DIAGNOSIS AND TREATMENT OF VIRAL INFECTION | CHIRON CORPORATION | 2001-10-16 | — | — | US | disclosed |
| EP-1142993-A1 | NOVEL SERINE PROTEASE BSSP5 | FUSO PHARMACEUTICAL INDUSTRIES LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-0819249-B1 | SENSITIVE IMMUNOASSAYS UTILIZING ANTIBODY CONJUGATES WITH REPLICABLE DNA TEMPLATES | BAYER AG (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6297370-B1 | NUCLEOTIDE SEQUENCES CODING SEGMENTS OF VIRAL GENOME; FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF VIRAL INFECTIONS | CHIRON CORPORATION | 2001-10-02 | — | — | US | disclosed |
| EP-1132475-A1 | NOVEL SERINE PROTEASE BSSP2 | FUSO PHARMACEUTICAL INDUSTRIES LTD. (JP) | 2001-09-12 | — | — | EP | disclosed |
| EP-1132477-A1 | NOVEL SERINE PROTEASES BSSP4 | FUSO PHARMACEUTICAL INDUSTRIES LTD. (JP) | 2001-09-12 | — | — | EP | disclosed |
| EP-1132473-A1 | NOVEL SERINE PROTEASE BSSP6 | FUSO PHARMACEUTICAL INDUSTRIES LTD. (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-6287565-B1 | PEPTIDE | CEL-SCI CORPORATION | 2001-09-11 | — | — | US | disclosed |
| EP-1129724-A2 | Vaccines for treating colon cancer | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2001-09-05 | — | — | EP | disclosed |
| EP-0318216-B2 | NANBV diagnostics | CHIRON CORP (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2001060411-A1 | PHARMACEUTICAL COMPOSITION, REAGENT AND METHOD FOR INTRACEREBRAL DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENT OR LABELING SUBSTANCE | KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY (JP) | 2001-08-23 | — | — | WO | disclosed |
| WO-2001057067-A1 | LIGAND FOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR | SUPRATEK PHARMA INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| EP-1122543-A1 | Immunoassay for human medullasin and multiple sclerosis | DAINICHISEIKA COLOR & CHEMICALS MFG. CO. LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001046696-A2 | METHODS AND COMPOSITIONS FOR DETECTING HEPATITIS E VIRUS | ABBOTT LABORATORIES (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1108786-A1 | NOVEL COLLECTIN | FUSO PHARMACEUTICAL INDUSTRIES LTD. (JP) | 2001-06-20 | — | — | EP | disclosed |
| EP-1102788-A2 | PREVENTION AND TREATMENT OF VIRAL DISEASE | THE UNIVERSITY OF MONTANA (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-1092772-A1 | ANTIBODY AGAINST LAR PHOSPHATASE SUBUNIT | FUSO PHARMACEUTICAL INDUSTRIES LTD. (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-6214583-B1 | POLYPEPTIDES ASSOCIATED WITH VIRAL DISEASE; FOR THE DETECTION, TREATMENT AND PREVENTION OF HEPATITIS VIRUS INFECTION | CHIRON CORPORATION | 2001-04-10 | — | — | US | disclosed |
| WO-2001022995-A1 | A METHOD FOR PREPARING CONJUGATES BETWEEN AN ANTIGEN AND MUCOSAL BINDING COMPONENT | NOVO NORDISK A/S (DK) | 2001-04-05 | — | — | WO | disclosed |
| US-6190864-B1 | HYBRIDIZATION TO DETECT PRESENCE OF HEPATITIS C VIRUS NUCLEIC ACIDS USING OLIGONUCLEOTIDES OF DEFINED NUCLEOTIDE SEQUENCES; GENOTYPING | CHIRON CORPORATION | 2001-02-20 | — | — | US | disclosed |
| US-6190860-B1 | USING DNA PROBE WHICH HYBRIDIZES TO NUCLEOTIDE SEQUENCE WHICH CODES FOR GLYCOPROTEIN 55; DIAGNOSIS OF CYTOMEGALO VIRUS | CHIRON CORPORATION | 2001-02-20 | — | — | US | disclosed |
| US-6187284-B1 | REACTING A PEPTIDE COMPRISING A FREE THIOL GROUP WITH AN 18 F-BOUND LABELLING REAGENT WHICH ALSO HAS A GROUP THAT IS REACTIVE WITH THIOLS. | IMMUNOMEDICS, INC. | 2001-02-13 | — | — | US | disclosed |
| US-6171782-B1 | ANTI-HEPATITIS C VIRUS ANTIBODY WHICH IS REACTIVE WITH A PEPTIDE OF AT LEAST 8 AMINO ACIDS (OCTAPEPTIDE); FOR IMMUNOASSAY DIAGNOSIS | CHIRON CORPORATION | 2001-01-09 | — | — | US | disclosed |
| US-6159502-A | Oral delivery systems for microparticles | BIOTECH AUSTRALIA PTY LTD (AU) | 2000-12-12 | — | — | US | disclosed |
| US-6156495-A | Hepatitis GB virus recombinant proteins and uses thereof | ABBOTT LABORATORIES (US) | 2000-12-05 | — | — | US | disclosed |
| US-6150087-A | NON-HEPATITIS A OR B VIRUS POLYPEPTIDE WHICH IS CAPABLE OF ILLICITING IMMUNE RESPONSE WITH HEPATITUS VIRUS ANTIBODIES, FOR THE TREATMENT OF AND PREVENTION OF VIRAL INFECTIONS | CHIRON CORPORATION (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000066090-A1 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES | BIOTECH AUSTRALIA PTY LIMITED (AU) | 2000-11-09 | — | — | WO | disclosed |
| EP-1041999-A1 | THROMBOGENIC POLYPEPTIDE CHIMERAS AND CONJUGATES HAVING ACTIVITY DEPENDENT UPON ASSOCIATION WITH TUMOR VASCULAR ENDOTHELIUM | Nuvas LLC (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-0929316-A4 | NOVEL PRODUCT AND PROCESS FOR T LYMPHOCYTE VETO | NAT JEWISH CT IMMUN & RESPIRAT (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1037909-A2 | POSTWEANING MULTISYSTEMIC WASTING SYNDROME VIRUS FROM PIGS | The University of Saskatchewan (CA) | 2000-09-27 | — | — | EP | disclosed |
| EP-1034785-A2 | Hepatitis C virus diagnostics and vaccines | CHIRON CORPORATION (US) | 2000-09-13 | — | — | EP | disclosed |
| US-6103239-A | EFFECTIVE IN ELICITING A THI DIRECTED IMMUNE RESPONSE AND PROVIDES A VACCINE COMPOSITION FOR TREATING OR PREVENTING AIDS. | CEL-SCI CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| EP-1023605-A1 | METHODS AND COMPOSITIONS FOR DETECTING HEPATITIS E VIRUS | Abbott Laboratories (US) | 2000-08-02 | — | — | EP | disclosed |
| US-6096315-A | IMMUNOMODULATORS FOR DISEASE PREVENTION | CEL SCI CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-6096541-A | HEPATOCYTE CELL CULTURE WHICH REPLICATES HEPATITIS C VIRUS; FOR SCREENING VIRICIDES | CHIRON CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-6083689-A | Sensitive immunoassays utilizing antibody conjugates with replicable DNA templates | BAYER CORPORATION (US) | 2000-07-04 | — | — | US | disclosed |
| US-6080846-A | RECOMBINANT DNA OF NUCLEOTIDE SEQUENCE CODING FOR B EPITOPE OF ENV GLYCOPROTEIN OF AN IMMUNODEFICIENCY VIRUS LINKED TO T EPITOPE OF NEF PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS-1; FOR PROTECTIVE VACCINES; DIAGNOSIS | INSTITUT PASTEUR (FR) | 2000-06-27 | — | — | US | disclosed |
| EP-1009726-A1 | FLUORINATION OF PROTEINS AND PEPTIDES FOR F-18 POSITRON EMISSION TOMOGRAPHY | Immunomedics, Inc. (US) | 2000-06-21 | — | — | EP | disclosed |
| US-6074816-A | OLIGONUCLEOTIDES WHICH HYBRIDIZE TO GENOME OF NON A AND NON B HEPATITIS VIRUS; FOR PROBES AND PRIMERS | CHIRON CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| US-6071693-A | FORMING HYBRIDIZATION PRODUCT WITH HEPATITIS C VIRUS NUCLEIC ACID; INCUBATION OF NON-HEPATITIS C VIRUS NUCLEOTIDE SEQUENCE OF EIGHT OR MORE CONTIGUOUS NUCLEOTIDES WITH HEPATITIS C VIRUS SEQUENCES, SCREEN FOR HYBRIDIZATION PRODUCTS | CHIRON CORPORATION (US) | 2000-06-06 | — | — | US | disclosed |
| US-6051374-A | DETECTING NUCLEIC ACID BY HYBRIDIZING TEST SAMPLE TO A POSITIVE STRANDED RNA GENOME COMPRISING OF AN OPEN READING FRAME ENCODING A POLYPROTEIN; VACCINES | ABBOTT LABORATORIES (US) | 2000-04-18 | — | — | US | disclosed |
| US-6045774-A | DIAGNOSIS OF CANCER AND OTHER DISORDERS | EPICYTE PHARMACEUTICAL INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-6027729-A | AN ISOLATED POLYPEPTIDE COMPRISING AN AMINO ACID SEQUENCE OF AT LEAST 12 CONTIGUOUS AMINO ACIDS ENCODED BY A NON-A, NON-B HEPATITIS VIRUS, I.E., HEPITITIS C, GENOME; MANAGING INFECTION SPREAD; MEDICAL DIAGNOSIS; EVALUATION OF LIBRARY | CHIRON CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| WO-2000008043-A2 | PREVENTION AND TREATMENT OF VIRAL DISEASE | THE UNIVERSITY OF MONTANA (US) | 2000-02-17 | — | — | WO | disclosed |
| EP-0419182-B1 | New HCV isolate J-1 | OYA AKIRA DR (JP) | 2000-01-19 | — | — | EP | disclosed |
| EP-0745128-A4 | HEPATITIS B VIRUS MUTANTS, REAGENTS AND METHODS FOR DETECTION | ABBOTT LAB (US) | 2000-01-12 | — | — | EP | disclosed |
| EP-0966296-A1 | CONJUGATED PEPTIDES, IMMUNOLOGICAL REAGENT CONTAINING SAME AND USE THEREOF FOR TREATMENT OF IMMUNOLOGICAL DISORDERS | Cel-Sci Corporation (US) | 1999-12-29 | — | — | EP | disclosed |
| US-5986052-A | Fusion polypeptide containing fragments of cartilage matrix protein and link protein | THE GENERAL HOSPITAL CORPORATION (US) | 1999-11-16 | — | — | US | disclosed |
| US-5981172-A | PROBE FOR VIRAL UNTRANSLATED REGION; DETECTING VIRAL NUCLEIC ACIDS; DEVEOLPING VACCINES AND ANTIBODIES TO USE AS DIAGNOSTIC TOOL IN DETECTING PRESENCE OF VIRUS | ABBOTT LABORATORIES (US) | 1999-11-09 | — | — | US | disclosed |
| US-5959092-A | THESE NEW ISOLATES COMPRISE NUCLEOTIDE AND AMINO ACID SEQUENCES WHICH ARE DISTINCT FROM THE PROTOTYPE HCV ISOLATE, HCV1. THUS, J1 AND J7 PROVIDE NEW POLYNUCLEOTIDES AND POLYPEPTIDES FOR USE, INTER ALIA, IN DIAGNOSTICS, RECOMBINANT | CHIRON CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0939128-A2 | New HCV isolates | Oya, Akira, Dr., Director General of the National Institute of Health of Japan, on behalf of The National Institute of Japan (JP) | 1999-09-01 | — | — | EP | disclosed |
| US-5932219-A | POLYPEPTIDES | CHIRON CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0929316-A1 | NOVEL PRODUCT AND PROCESS FOR T LYMPHOCYTE VETO | NATIONAL JEWISH CENTER FOR IMMUNOLOGY AND RESPIRATORY MEDICINE (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5925512-A | MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TO MUTANT HEPATITIS B VIRUS SURFACE ANTIGEN ?A? DETERMINANT | ABBOTT LABORATORIES (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1999032143-A1 | THROMBOGENIC POLYPEPTIDE CHIMERAS AND CONJUGATES HAVING ACTIVITY DEPENDENT UPON ASSOCIATION WITH TUMOR VASCULAR ENDOTHELIUM | NUVAS LLC (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999029717-A2 | POSTWEANING MULTISYSTEMIC WASTING SYNDROME VIRUS FROM PIGS | UNIVERSITY OF SASKATCHEWAN (CA) | 1999-06-17 | — | — | WO | disclosed |
| EP-0541692-B1 | HERPES SIMPLEX VIRUS VP16 VACCINES | CHIRON CORP (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1999019732-A1 | METHODS AND COMPOSITIONS FOR DETECTING HEPATITIS E VIRUS | ABBOTT LABORATORIES (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0819249-A4 | SENSITIVE IMMUNOASSAYS UTILIZING ANTIBODY CONJUGATES WITH REPLICABLE DNA TEMPLATES | CHIRON DIAGNOSTICS CORP (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0906337-A2 | AN ANTIGENIC EPITOPE OF THE u A /u DETERMINANT OF HEPATITIS B SURFACE ANTIGEN AND USES THEREOF | Abbott Laboratories (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1999011590-A1 | FLUORINATION OF PROTEINS AND PEPTIDES FOR F-18 POSITRON EMISSION TOMOGRAPHY | IMMUNOMEDICS, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| US-5872094-A | ANCHORING POLYPEPTIDES OF FRAGMENT OF HUMAN CARTILAGE PROTEIN BINDING TO HUMAN PROTEIN OR COLLAGEN | THE GENERAL HOSPITAL CORPORATION (US) | 1999-02-16 | — | — | US | disclosed |
| US-5871903-A | ADMINISTERING TO A MAMMAL AN ANTIGEN COMPRISING PREFERENTIAL AMINO ACID SEQUENCE OR ENCODED BY A POLYNUCLEOTIDE SEQUENCES FROM HEPATITIS C VIRUS POLYNUCLEOTIDE SEQUENCE OR FRAGMENT, INCUBATING WITH SAMPLE TO FORM ANTIBODY-ANTIGEN COMPLEX | CHIRON CORPORATION (US) | 1999-02-16 | — | — | US | disclosed |
| US-5856437-A | Hepatitis C virus isolate polypeptides | CHIRON CORPORATION (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0717753-B1 | RIBOSOME INACTIVATING PROTEINS EXTRACTED FROM SEEDS OF SAPONARIA OCYMOIDES AND VACCARIA PYRAMIDATA, THEIR PREPARATION AND IMMUNOTOXINS CONTAINING THEM | MENARINI RICERCHE SPA (IT) | 1998-12-02 | — | — | EP | disclosed |
| US-5843450-A | Hepatitis GB Virus synthetic peptides and uses thereof | ABBOTT LABORATORIES (US) | 1998-12-01 | — | — | US | disclosed |
| US-5843887-A | Compositions for delivery of polypeptides, and methods | ALLIED MEDICAL RESEARCH ASSOCIATES (US) | 1998-12-01 | — | — | US | disclosed |
| US-5834591-A | VACCINES FOR INFECTIONS CAUSED BY MICROORGANISMS SUCH AS NEISSERIA | WASHINGTON UNIVERSITY (US) | 1998-11-10 | — | — | US | disclosed |
| US-5834307-A | RECOMBINANT POLYNUCLEOTIDE WHICH CODES FOR A POLYPEPTIDE FROM A CYTOMEGALOVIRUS GLYCOPROTEIN; FOR VACCINES, DIAGNOSIS | CHIRON CORPORATION (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0593112-B1 | Detection of antibiotics | GIST BROCADES NV (NL) | 1998-08-26 | — | — | EP | disclosed |
| US-5795579-A | COMPRISED OF IMMUNOGENIC POLYPEPTIDES CAPABLE OF ELICITUNG CELLULAR IMMUNE RESPONSE | CHIRON CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0857059-A1 | NOVEL ADJUVANT COMPOSITIONS AND VACCINE FORMULATIONS COMPRISING SAME | RESEARCH TRIANGLE PHARMACEUTICALS LTD. (US) | 1998-08-12 | — | — | EP | disclosed |
| US-5785975-A | PHOSPHOLIPIDPOLYSACCHARIDE | RESEARCH TRIANGLE PHARMACEUTICALS (US) | 1998-07-28 | — | — | US | disclosed |
| WO-1998030591-A1 | NOVEL EPITHELIAL TISSUE IMAGING AGENT | EPICYTE PHARMACEUTICAL INC. (US) | 1998-07-16 | — | — | WO | disclosed |
| WO-1998028002-A1 | A NOVEL PATHOGENIC COCCOID ORGANISM, STAPHYLOCOCCUS LEEI, WITH TROPHISM FOR GASTRIC MUCIN | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 1998-07-02 | — | — | WO | disclosed |
| US-5766845-A | IN VITRO DIAGNOSTIC METHOD FOR DETECTING HUMAN ANTIBODIES TO HEPATITIS C VIRUS | CHIRON CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| US-5756361-A | Screening method for periodontal disease | METRA BIOSYSTEMS, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5756312-A | DNA MOLECULE ENCODING POLYPEPTIDE COMPRISING TWO HETEROGENEOUS AMINO ACID SEQUENCES FROM SAME VARIABLE DOMAIN OF HEPATITIS C VIRUS ISOLATES | CHIRON CORPORATION (US) | 1998-05-26 | — | — | US | disclosed |
| US-5750350-A | KIT CONTAINING ANTIBODIES | CHIRON CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| US-5747044-A | Hepatitis delta diagnostics and vaccines | CHIRON CORPORATION (US) | 1998-05-05 | — | — | US | disclosed |
| US-5736344-A | DETERMINING BONE COLLAGEN DECOMPOSITION BY REACTING BLOOD SAMPLE WITH ANTIBODY(WHICH IS SPECIFIC FOR PYRIDINOLINES) TO FORM AN IMMUNOCOMPLEX WHICH CAN BE MEASURED TO INDICATE LEVELS OF COLLAGEN BREAKDOWN | METRA BIOSYSTEMS, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| US-5728520-A | HEPATITIS TYPE C VIRAL EPITOPES | CHIRON CORPORATION (US) | 1998-03-17 | — | — | US | disclosed |
| WO-1998006416-A1 | CONJUGATED PEPTIDES, IMMUNOLOGICAL REAGENT CONTAINING SAME AND USE THEREOF FOR TREATMENT OF IMMUNOLOGICAL DISORDERS | CEL-SCI CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
| US-5714152-A | GENETIC ENGINEERED POLYPEPTIDE | CHIRON CORPORATION (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0819249-A1 | SENSITIVE IMMUNOASSAYS UTILIZING ANTIBODY CONJUGATES WITH REPLICABLE DNA TEMPLATES | Chiron Diagnostics Corporation (US) | 1998-01-21 | — | — | EP | disclosed |
| US-5698390-A | INCUBATING SAMPLE INCLUDING HEPATITIS C POLYPEPTIDE THAT BINDS TO ANTIBODY UNDER CONDITIONS THAT ALLOW FOR FORMATION OF ANTIBODY-ANTIGEN COMPLEX | CHIRON CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| US-5688914-A | Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus | INSTITUT PASTEUR (FR) | 1997-11-18 | — | — | US | disclosed |
| WO-1997039029-A2 | AN ANTIGENIC EPITOPE OF THE A DETERMINANT OF HEPATITIS B SURFACE ANTIGEN AND USES THEREOF | ABBOTT LABORATORIES (US) | 1997-10-23 | — | — | WO | disclosed |
| WO-1997037687-A1 | NOVEL PRODUCT AND PROCESS FOR T LYMPHOCYTE VETO | NATIONAL JEWISH CENTER FOR IMMUNOLOGY AND RESPIRATORY MEDICINE (US) | 1997-10-16 | — | — | WO | disclosed |
| US-5670152-A | CONTAINING HEPATITIS VIRUS EPITOPES | CHIRON CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5670153-A | HEPATITIS TYPE C VIRAL EPITOPES FOR IMMUNOLOGY | CHIRON CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0794434-A1 | METHOD FOR THE ANALYSIS OF ALLERGEN | ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1997-09-10 | — | — | EP | disclosed |
| EP-0790312-A2 | Target cell specific vectors for the insertion of genes into cells, medicament containing such vectors and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-08-20 | — | — | EP | disclosed |
| EP-0531497-B1 | ORAL DELIVERY SYSTEMS FOR MICROPARTICLES | BIOTECH AUSTRALIA PTY LTD (AU) | 1997-08-13 | — | — | EP | disclosed |
| US-5652342-A | Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same | CEL-SCI CORPORATION (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0781142-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYPEPTIDES | ALLIED MEDICAL RESEARCH ASSOCIATES (US) | 1997-07-02 | — | — | EP | disclosed |
| US-5595739-A | DIAGNOSIS, VACCINES | ABBOTT LABORATORIES (US) | 1997-01-21 | — | — | US | disclosed |
| WO-1997001330-A1 | NOVEL ADJUVANT COMPOSITIONS AND VACCINE FORMULATIONS COMPRISING SAME | RESEARCH TRIANGLE PHARMACEUTICALS (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5593825-A | Hepatitis B virus mutants, reagents and methods for detection | ABBOTT LABORATORIES (US) | 1997-01-14 | — | — | US | disclosed |
| US-5591440-A | Hepatitis B Virus mutants, reagents and methods for detection | ABBOTT LABORATORIES (US) | 1997-01-07 | — | — | US | disclosed |
| EP-0747394-A2 | Hepatitis GB virus synthetic peptides and uses thereof | ABBOTT LABORATORIES (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0747482-A2 | Hepatitis GB virus recombinant proteins and uses thereof | ABBOTT LABORATORIES (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0745128-A1 | HEPATITIS B VIRUS MUTANTS, REAGENTS AND METHODS FOR DETECTION | ABBOTT LABORATORIES (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0745129-A1 | NON-A, NON-B, NON-C, NON-D, NON-E HEPATITIS REAGENTS AND METHODS FOR THEIR USE | Abbott Laboratories (US) | 1996-12-04 | — | — | EP | disclosed |
| WO-1996032640-A1 | SENSITIVE IMMUNOASSAYS UTILIZING ANTIBODY CONJUGATES WITH REPLICABLE DNA TEMPLATES | CHIRON DIAGNOSTICS CORPORATION (US) | 1996-10-17 | — | — | WO | disclosed |
| EP-0736601-A2 | Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use | Abbott Laboratories (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5547834-A | MODIFIED ENDOPROTEOLYTIC CLEAVAGE SITES | CHIRON CORPORATION (US) | 1996-08-20 | — | — | US | disclosed |
| US-5547667-A | DRUG DELIVERY | FARMITALIA CARLO ERBA S.R.L. (IT) | 1996-08-20 | — | — | US | disclosed |
| EP-0717753-A1 | RIBOSOME INACTIVATING PROTEINS EXTRACTED FROM SEEDS OF SAPONARIA OCYMOIDES AND VACCARIA PYRAMIDATA, THEIR PREPARATION AND IMMUNOTOXINS CONTAINING THEM | Menarini Ricerche S.p.A. (IT) | 1996-06-26 | — | — | EP | disclosed |
| EP-0679089-A4 | METHODS FOR PROMOTING CARTILAGE MATRIX FORMATION. | GEN HOSPITAL CORP (US) | 1996-05-29 | — | — | EP | disclosed |
| JP-H08126489-A | BASE MATERIAL FOR CARRYING ENZYME, ENZYME CARRIER AND PRODUCTION THEREOF | OSAKA PREFECTURE | 1996-05-21 | — | — | JP | disclosed |
| EP-0495053-B1 | NEW LINKER FOR BIOACTIVE AGENTS | PHARMACIA SPA (IT) | 1996-03-27 | — | — | EP | disclosed |
| US-5501988-A | CANCER DETECTION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-26 | — | — | US | disclosed |
| WO-1996006632-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYPEPTIDES | ALLIED MEDICAL RESEARCH ASSOCIATES (US) | 1996-03-07 | — | — | WO | disclosed |
| EP-0449955-B1 | SYNTHETIC HIV-LIKE PEPTIDES, THEIR COMPOSITIONS AND USES | CLARITY TECHNOLOGIES INC (US) | 1996-03-06 | — | — | EP | disclosed |
| EP-0697888-A1 | CONSERVED MOTIF OF HEPATITIS C VIRUS E2/NS1 REGION | CHIRON CORPORATION (US) | 1996-02-28 | — | — | EP | disclosed |
| JP-H0853499-A | OLIGOMER OF FAB FRAGMENT OF CHIMERA ANTIBODY | GREEN CROSS CORP:THE | 1996-02-27 | — | — | JP | disclosed |
| US-5486472-A | POLYPEPTIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-23 | — | — | US | disclosed |
| EP-0420913-B1 | HETEROFUNCTIONAL CELLULAR IMMUNOLOGICAL REAGENTS, VACCINES CONTAINING SAME AND METHODS FOR THE USE OF SAME | CELL MED INC (US) | 1995-11-15 | — | — | EP | disclosed |
| EP-0679089-A1 | METHODS FOR PROMOTING CARTILAGE MATRIX FORMATION | THE GENERAL HOSPITAL CORPORATION (US) | 1995-11-02 | — | — | EP | disclosed |
| WO-1995021922-A2 | NON-A, NON-B, NON-C, NON-D, NON-E HEPATITIS REAGENTS AND METHODS FOR THEIR USE | ABBOTT LABORATORIES (US) | 1995-08-17 | — | — | WO | disclosed |
| US-5442043-A | Penetration brain-blood barrier; drug delivery | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-08-15 | — | — | US | disclosed |
| EP-0662839-A1 | VACCINES AND ANTIGENIC CONJUGATES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-07-19 | — | — | EP | disclosed |
| US-5434053-A | Cephalosporin antibiotics by detection by labeling with albumin | GIST-BROCADES N.V. (NL) | 1995-07-18 | — | — | US | disclosed |
| US-5427917-A | Using bound or labeled antibodies capable of binding to enzyme; quantitative analysis of product; spectrophotometry | TEIJIN LIMITED (JP) | 1995-06-27 | — | — | US | disclosed |
| EP-0463859-B1 | Immobilization of biomolecules by enhanced electrophoretic precipitation | LILLY CO ELI (US) | 1995-05-17 | — | — | EP | disclosed |
| US-5403716-A | Method for measurement of tissue factor in high sensitivity and measurement kit therefor | TEIJIN LIMITED (JP) | 1995-04-04 | — | — | US | disclosed |
| WO-1995007297-A1 | RIBOSOME INACTIVATING PROTEINS EXTRACTED FROM SEEDS OF SAPONARIA OCYMOIDES AND VACCARIA PYRAMIDATA, THEIR PREPARATION AND IMMUNOTOXINS CONTAINING THEM | MENARINI RICERCHE SUD S.P.A. (IT) | 1995-03-16 | — | — | WO | disclosed |
| EP-0608261-A4 | IMMUNOREACTIVE HEPATITIS C VIRUS POLYPEPTIDE COMPOSITIONS. | CHIRON CORP (US) | 1995-03-15 | — | — | EP | disclosed |
| US-5389528-A | Isolated DNA sequence encoding polypeptide identifiable as component of hepatitis delta antigen | CHIRON CORPORATION (US) | 1995-02-14 | — | — | US | disclosed |
| US-5387578-A | Releasing drugs from bioactive agents in order to improve the therapeutic efficacy and reduce their toxic effects | FARMITALIA CARLO ERBA S.R.L. (IT) | 1995-02-07 | — | — | US | disclosed |
| US-5378814-A | Hepatitis delta viral polypeptides | CHIRON CORPORATION (US) | 1995-01-03 | — | — | US | disclosed |
| US-5372928-A | Detecting hepatitis C virus polynucleotide in test sample by contacting with probe containing complementary sequence, detecting duplexes formed | CHIRON CORPORATION (US) | 1994-12-13 | — | — | US | disclosed |
| WO-1994026904-A1 | HEPATITIS B VIRUS MUTANTS, REAGENTS AND METHODS FOR DETECTION | ABBOTT LABORATORIES (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994026306-A1 | CONSERVED MOTIF OF HEPATITIS C VIRUS E2/NS1 REGION | CHIRON CORPORATION (US) | 1994-11-24 | — | — | WO | disclosed |
| US-5366861-A | Immunoassay and reagent kit used therefor | TEIJIN LIMITED (JP) | 1994-11-22 | — | — | US | disclosed |
| US-5350671-A | Detection of antibodies that bind hepatitis C | CHIRON CORPORATION (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1994018217-A1 | NON-A, NON-B, NON-C, NON-D, NON-E HEPATITIS REAGENTS AND METHODS FOR THEIR USE | ABBOTT LABORATORIES (US) | 1994-08-18 | — | — | WO | disclosed |
| EP-0421392-B1 | Anti-hCG-beta core monoclonal antibody, its production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-08-17 | — | — | EP | disclosed |
| EP-0609580-A1 | Recombinant CMV neutralising proteins | CHIRON CORPORATION (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0608261-A1 | IMMUNOREACTIVE HEPATITIS C VIRUS POLYPEPTIDE COMPOSITIONS | CHIRON CORPORATION (US) | 1994-08-03 | — | — | EP | disclosed |
| WO-1994015627-A1 | METHODS FOR PROMOTING CARTILAGE MATRIX FORMATION | THE GENERAL HOSPITAL CORPORATION (US) | 1994-07-21 | — | — | WO | disclosed |
| EP-0328679-B1 | IMMUNOASSAYING METHOD AND REAGENT KIT FOR IT | TEIJIN LTD (JP) | 1994-07-13 | — | — | EP | disclosed |
| EP-0184701-B1 | A method for determining a ligand | HOECHST CELANESE CORP (US) | 1994-06-08 | — | — | EP | disclosed |
| EP-0599303-A2 | Peptide conjugate | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-06-01 | — | — | EP | disclosed |
| EP-0439601-B1 | COMPOSITION CONTAINING A B EPITOPE OF THE ENVELOPE GLYCOPROTEIN OF A RETROVIRUS AND A T EPITOPE OF A DISTINCT PROTEIN FROM THIS VIRUS | PASTEUR INSTITUT (FR) | 1994-05-04 | — | — | EP | disclosed |
| EP-0593112-A1 | Detection of antibiotics | GIST-BROCADES N.V. (NL) | 1994-04-20 | — | — | EP | disclosed |
| WO-1994007530-A1 | VACCINES AND ANTIGENIC CONJUGATES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1994-04-14 | — | — | WO | disclosed |
| EP-0591431-A1 | HEPATITIS C VIRUS (HCV) POLYPEPTIDES | CHIRON CORPORATION (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1994006015-A1 | METHOD TO MONITOR DRUG THERAPY AND ASSESS METASTASIS | THE ROWETT RESEARCH INSTITUTE (GB) | 1994-03-17 | — | — | WO | disclosed |
| US-5288517-A | Method of forming planar membrane | CANON KABUSHIKI KAISHA (JP) | 1994-02-22 | — | — | US | disclosed |
| EP-0251575-B1 | Hepatitis delta diagnostics and vaccines, their preparation and use | CHIRON CORP (US) | 1994-01-26 | — | — | EP | disclosed |
| EP-0531497-A4 | ORAL DELIVERY SYSTEMS FOR MICROPARTICLES | — | 1993-12-22 | — | — | EP | disclosed |
| EP-0328939-B1 | Method, reagent, kit and monoclonal antibody for diagnosing cancer in human digestive organs by determining acid glutathione S-transferase | TEIJIN LTD (JP) | 1993-12-22 | — | — | EP | disclosed |
| EP-0318216-B1 | NANBV diagnostics and vaccines | CHIRON CORP (US) | 1993-12-15 | — | — | EP | disclosed |
| US-5260189-A | Immunospecific reagent comprising at least one synthetic peptide conjugated through its C-terminus to carrier protein; diagnostic kit containing it; determining presence or amount of antibodies to HIV-1 in fluid sample with reagent | IMMUNODIAGNOSTICS, INC. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0355847-B1 | Method of forming planar membrane | CANON KK (JP) | 1993-10-27 | — | — | EP | disclosed |
| WO-1993006126-A1 | IMMUNOREACTIVE HEPATITIS C VIRUS POLYPEPTIDE COMPOSITIONS | CHIRON CORPORATION (US) | 1993-04-01 | — | — | WO | disclosed |
| EP-0532757-A1 | HIGHLY SENSITIVE ASSAY OF TISSUE FACTOR AND KIT THEREFOR | TEIJIN LIMITED (JP) | 1993-03-24 | — | — | EP | disclosed |
| EP-0531497-A1 | ORAL DELIVERY SYSTEMS FOR MICROPARTICLES. | BIOTECH AUSTRALIA PTY LTD (AU) | 1993-03-17 | — | — | EP | disclosed |
| EP-0522159-A1 | ANTIBODY TO PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE-PACAP, HYBRIDOMA AND ASSAY FOR PACAP | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-01-13 | — | — | EP | disclosed |
| WO-1993000365-A2 | HEPATITIS C VIRUS (HCV) POLYPEPTIDES | CHIRON CORPORATION (US) | 1993-01-07 | — | — | WO | disclosed |
| US-5166063-A | IMMOBOLIZATION OF BIOMOLECULES BY ENHANCED ELECTROPHORETIC PRECIPITATION | ELI LILLY AND COMPANY (US) | 1992-11-24 | — | — | US | disclosed |
| EP-0449955-A4 | SYNTHETIC HIV-LIKE PEPTIDES, THEIR COMPOSITIONS AND USES | — | 1992-10-28 | — | — | EP | disclosed |
| US-5157123-A | S-(2-THIOPYRIDYL)-L-CYSTEINE, A HETEROBIFUNCTIONAL CROSSLINKING REAGENT | GEORGETOWN UNIVERSITY (US) | 1992-10-20 | — | — | US | disclosed |
| WO-1992017167-A1 | ORAL DELIVERY SYSTEMS FOR MICROPARTICLES | BIOTECH AUSTRALIA PTY. LTD. (AU) | 1992-10-15 | — | — | WO | disclosed |
| WO-1992013871-A1 | POLYPEPTIDES AND POLYNUCLEOTIDES USEFUL FOR THE DIAGNOSIS AND TREATMENT OF PATHOGENIC NEISSERIA | WASHINGTON UNIVERSITY (US) | 1992-08-20 | — | — | WO | disclosed |
| EP-0495053-A1 | NEW LINKER FOR BIOACTIVE AGENTS. | ERBA CARLO SPA (IT) | 1992-07-22 | — | — | EP | disclosed |
| US-5128241-A | MICROCAPSULE IMMUNOASSAY AND REAGENTS THEREFOR | HITACHI, LTD. (JP) | 1992-07-07 | — | — | US | disclosed |
| EP-0199480-B1 | HEPATITIS A VIRUS VACCINES | CHIRON CORPORATION (US) | 1992-07-01 | — | — | EP | disclosed |
| EP-0436537-A4 | RECOMBINANT CMV NEUTRALIZING PROTEINS | — | 1992-04-08 | — | — | EP | disclosed |
| WO-1992002255-A1 | NEW LINKER FOR BIOACTIVE AGENTS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1992-02-20 | — | — | WO | disclosed |
| EP-0463859-A2 | Immobilization of biomolecules by enhanced electrophoretic precipitation | ELI LILLY AND COMPANY (US) | 1992-01-02 | — | — | EP | disclosed |
| EP-0452503-A1 | IMMUNOASSAY OF HUMAN THROMBOMODULIN, AND REAGENT AND KIT THEREFOR | TEIJIN LIMITED (JP) | 1991-10-23 | — | — | EP | disclosed |
| EP-0449955-A1 | SYNTHETIC HIV-LIKE PEPTIDES, THEIR COMPOSITIONS AND USES. | IMMUNODIAGNOSTICS INC (US) | 1991-10-09 | — | — | EP | disclosed |
| WO-1991014786-A1 | ANTIBODY TO PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE-PACAP, HYBRIDOMA AND ASSAY FOR PACAP | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-10-03 | — | — | WO | disclosed |
| EP-0420913-A4 | HETEROFUNCTIONAL CELLULAR IMMUNOLOGICAL REAGENTS, VACCINES CONTAINING SAME AND METHODS FOR THE USE OF SAME | — | 1991-09-11 | — | — | EP | disclosed |
| EP-0436537-A1 | RECOMBINANT CMV NEUTRALIZING PROTEINS | CHIRON CORPORATION (US) | 1991-07-17 | — | — | EP | disclosed |
| EP-0431169-A1 | IMMUNOASSAY METHOD, REAGENT AND KIT | TEIJIN LIMITED (JP) | 1991-06-12 | — | — | EP | disclosed |
| EP-0421392-A1 | Anti-hCG-beta core monoclonal antibody, its production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-04-10 | — | — | EP | disclosed |
| EP-0420913-A1 | HETEROFUNCTIONAL CELLULAR IMMUNOLOGICAL REAGENTS, VACCINES CONTAINING SAME AND METHODS FOR THE USE OF SAME. | CELL MED INC (US) | 1991-04-10 | — | — | EP | disclosed |
| WO-1991004262-A1 | NEW HCV ISOLATES | NATIONAL INSTITUTE OF HEALTH OF JAPAN (JP) | 1991-04-04 | — | — | WO | disclosed |
| EP-0419182-A1 | New HCV isolates | Oya, Akira, Dr., Director General of the National Institute of Health of Japan, on behalf of The National Institute of Japan (JP) | 1991-03-27 | — | — | EP | disclosed |
| WO-1990011089-A1 | NANBV DIAGNOSTICS AND VACCINES | CHIRON CORPORATION (US) | 1990-10-04 | — | — | WO | disclosed |
| WO-1990010621-A1 | SITE-SPECIFIC HETEROBIFUNCTIONAL CROSSLINKING REAGENTS | GEORGETOWN UNIVERSITY (US) | 1990-09-20 | — | — | WO | disclosed |
| JP-H02173000-A | NEO-GLYCOPROTEIN AND ITS PRODUCTION | BEHRINGWERKE AG | 1990-07-04 | — | — | JP | disclosed |
| WO-1990007119-A1 | SYNTHETIC HIV-LIKE PEPTIDES, THEIR COMPOSITIONS AND USES | IMMUNODIAGNOSTICS, INC. (US) | 1990-06-28 | — | — | WO | disclosed |
| JP-H02145199-A | METHOD FOR DETECTING NUCLEIC ACID | SHIMADZU CORP | 1990-06-04 | — | — | JP | disclosed |
| US-4914040-A | Complexing with mono (poly)/clonal antibodies | BOEHRINGER MANNHEIM GMBH (DE) | 1990-04-03 | — | — | US | disclosed |
| EP-0355847-A2 | Method of forming planar membrane | CANON KABUSHIKI KAISHA (JP) | 1990-02-28 | — | — | EP | disclosed |
| WO-1989012458-A1 | HETEROFUNCTIONAL CELLULAR IMMUNOLOGICAL REAGENTS, VACCINES CONTAINING SAME AND METHODS FOR THE USE OF SAME | CELL MED, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0328679-A1 | IMMUNOASSAYING METHOD AND REAGENT KIT FOR IT | TEIJIN LIMITED (JP) | 1989-08-23 | — | — | EP | disclosed |
| EP-0328939-A2 | Method, reagent, kit and monoclonal antibody for diagnosing cancer in human digestive organs by determining acid glutathione S-transferase | TEIJIN LIMITED (JP) | 1989-08-23 | — | — | EP | disclosed |
| WO-1989007143-A1 | RECOMBINANT CMV NEUTRALIZING PROTEINS | CHIRON CORPORATION (US) | 1989-08-10 | — | — | WO | disclosed |
| WO-1989004669-A1 | NANBV DIAGNOSTICS AND VACCINES | CHIRON CORPORATION (US) | 1989-06-01 | — | — | WO | disclosed |
| EP-0278116-A2 | A method for immunoassay and kit therefor | HITACHI, LTD. (JP) | 1988-08-17 | — | — | EP | disclosed |
| EP-0184701-A2 | A method for determining a ligand | HOECHST CELANESE CORPORATION (US) | 1986-06-18 | — | — | EP | disclosed |
| EP-0155224-A2 | Solid-borne complex bearing chromagen responsive functionality for antibody, antigen, receptor, or ligand detection | CHROMAGENICS, Inc. (US) | 1985-09-18 | — | — | EP | disclosed |
| EP-0040365-B1 | AN ASSAYING METHOD INVOLVING BIOSPECIFIC AFFINITY REACTIONS | PHARMACIA DIAGNOSTICS AB (SE) | 1985-08-21 | — | — | EP | disclosed |
| US-4507234-A | Conjugate having cytotoxicity and process for the preparation thereof | TEIJIN LIMITED (JP) | 1985-03-26 | — | — | US | disclosed |
| US-4507234-A | Conjugate having cytotoxicity and process for the preparation thereof | TEIJIN LIMITED (JP) | 1985-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (29 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021005-A1 | Pegylated Ion Channel Modulating Compounds | KCNN3, KCNN2, KCNN1 | ALDH1A1 2835/4885PKM 2410/4885KMT2A 4336/4885 |
| US-20040266694-A1 | Ligand for vascular endothelial growth factor receptor | FLT1, KDR, FLT4 | ALDH1A1 1956/4885PKM 4133/4885KMT2A 4729/4885 |
| US-20020137684-A1 | Ligand for enhancing oral and CNS delivery of biological agents | VIP, IGFBP6, GMFG | ALDH1A1 4186/4885PKM 4712/4885KMT2A 2326/4885 |
| US-20050123544-A1 | Prevention and treatment of amyloidogenic disease | APP, PSEN1, BACE1 | ALDH1A1 3735/4885PKM 4435/4885KMT2A 4236/4885 |
| US-20150307544-A1 | DITHIOAMINE REDUCING AGENTS | TMT1A, QSOX1, TST | ALDH1A1 1493/4885PKM 3186/4885KMT2A 1708/4885 |
| US-20190153025-A1 | Dithioamine Reducing Agents | TMT1A, QSOX1, TST | ALDH1A1 1493/4885PKM 3186/4885KMT2A 1708/4885 |
| US-20060127310-A1 | Amplification of biotin-mediated targeting | BTD, HLCS, SLC1A5 | ALDH1A1 1010/4885PKM 2176/4885KMT2A 2902/4885 |
| US-20020119096-A1 | Fluorination of proteins and peptides for F-18 positron emission tomography | FGB, FABP2, FUCA1 | ALDH1A1 3608/4885PKM 3059/4885KMT2A 2744/4885 |
| US-20150376591-A1 | SUBSTITUTED PYRAZINE DITHIOL REDUCING AGENTS | SPR, TST, SQOR | ALDH1A1 766/4885PKM 1586/4885KMT2A 3490/4885 |
| US-20130058869-A1 | Prevention And Treatment Of Amyloidogenic Disease | APP, PSEN1, BACE1 | ALDH1A1 3735/4885PKM 4435/4885KMT2A 4236/4885 |
| US-20050059591-A1 | Prevention and treatment of amyloidogenic disease | APP, PSEN1, BACE1 | ALDH1A1 3735/4885PKM 4435/4885KMT2A 4236/4885 |
| US-20130096278-A1 | THIOSULFONATE COMPOUND, REVERSIBLE CATIONIZATION AGENT FOR PROTEIN AND/OR PEPTIDE, AND METHOD FOR SOLUBILIZATION | TST, PTMS, SRP9 | ALDH1A1 4865/4885PKM 3814/4885KMT2A 4255/4885 |
| US-20020058619-A1 | Ligand for vascular endothelial growth factor receptor | FLT1, KDR, FLT4 | ALDH1A1 1956/4885PKM 4133/4885KMT2A 4729/4885 |
| US-20120189624-A1 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | TTR, APP, MME | ALDH1A1 3278/4885PKM 4590/4885KMT2A 3659/4885 |
| US-20110287049-A1 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES | IAPP, APP, TTR | ALDH1A1 4226/4885PKM 4341/4885KMT2A 4323/4885 |
| US-20090208487-A1 | Prevention and treatment of synucleinopathic and amyloidogenic disease | SNCA, PARK7, GAP43 | ALDH1A1 3120/4885PKM 2641/4885KMT2A 4626/4885 |
| US-20160024122-A1 | BIOREVERSIBLE BORONATES FOR DELIVERY OF MOLECULES INTO CELLS | BAG6, BCAP31, PHB1 | ALDH1A1 3874/4885PKM 1999/4885KMT2A 3068/4885 |
| US-20110166043-A1 | BIOMARKER DETECTION-2 | CPB2, NAALAD2, PRSS2 | ALDH1A1 1052/4885PKM 4150/4885KMT2A 1934/4885 |
| US-20130196433-A1 | Boronate-Mediated Delivery of Molecules into Cells | BCAP31, PHAX, BTD | ALDH1A1 4591/4885PKM 1855/4885KMT2A 3901/4885 |
| US-20050158304-A1 | Prevention and treatment of amyloidogenic disease | APP, PSEN1, BACE1 | ALDH1A1 3735/4885PKM 4435/4885KMT2A 4236/4885 |
| US-20060121038-A9 | Prevention and treatment of amyloidogenic disease | APP, PSEN1, BACE1 | ALDH1A1 3735/4885PKM 4435/4885KMT2A 4236/4885 |
| US-11555051-B2 | Dithioamine reducing agents | TMT1A, QSOX1, TST | ALDH1A1 1493/4885PKM 3186/4885KMT2A 1708/4885 |
| US-20120142902-A1 | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease | SNCA, PARK7, GAP43 | ALDH1A1 3120/4885PKM 2641/4885KMT2A 4626/4885 |
| US-20080175838-A1 | Prevention And Treatment of Synucleinopathic And Amyloidogenic Disease | SNCA, PARK7, GAP43 | ALDH1A1 3120/4885PKM 2641/4885KMT2A 4626/4885 |
| US-20130211055-A1 | DITHIOAMINE REDUCING AGENTS | SQOR, TST, TMT1A | ALDH1A1 904/4885PKM 3238/4885KMT2A 1208/4885 |
| US-20040146521-A1 | Prevention and treatment of synucleinopathic disease | SNCA, PARK7, GAP43 | ALDH1A1 3223/4885PKM 2384/4885KMT2A 4545/4885 |
| US-20060029617-A1 | Porcine circovirus and Helicobacter combination vaccines and methods of use | CD63, HAVCR2, GPKOW | ALDH1A1 4880/4885PKM 2622/4885KMT2A 3863/4885 |
| US-20030049253-A1 | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines | MICA, CD44, CD74 | ALDH1A1 3688/4885PKM 2785/4885KMT2A 3319/4885 |
| US-20090130049-A1 | Self-Sterilizing Products | NASP, ZP1, SPAG5 | ALDH1A1 575/4885PKM 1236/4885KMT2A 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.